Target Information
General Information of This Target (ID: PATR0EGDKN)
| Target Name | DNA topoisomerase 1 (TOP1) |
|||||
|---|---|---|---|---|---|---|
| Gene Name | TOP1 |
|||||
| Gene ID | ||||||
| Synonym | DNA topoisomerase I |
|||||
| Sequence |
MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKK
HKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEP EDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKD KDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKF YYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKC DFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGL FRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENI QGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALY FIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNK VPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQ QLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLAD ARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSK LNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF Click to Show/Hide
|
|||||
| Family | the type IB topoisomerase family |
|||||
| Function |
Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)- enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter.
Click to Show/Hide
|
|||||
| Uniprot Entry | ||||||
| HGNC ID | ||||||
| KEGG ID | ||||||
Full List of The ADC Related to This Target
Approved in 2019
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Trastuzumab deruxtecan
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DXd |
Mc-Gly-Gly-Phe-Gly |
|
|
Sacituzumab govitecan
[3]
|
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
SN-38 |
CL2A |
|
|
Datopotamab deruxtecan
|
Datopotamab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
DXd |
Mc-Gly-Gly-Phe-Gly |
|
|
Trastuzumab rezetecan
[4]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
Sacituzumab tirumotecan
|
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
KL610023 |
Pyrimidine CL2A carbonate linker |
Phase 3
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
GQ1005
|
Trastuzumab variant |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DXd |
Mc-Gly-Gly-Phe-Gly (ring-opening derivative) |
|
|
Patritumab deruxtecan
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
DXd |
Mc-Gly-Gly-Phe-Gly |
|
|
Ifinatamab deruxtecan
|
Ifinatamab |
CD276 antigen (CD276) |
DXd |
Mc-Gly-Gly-Phe-Gly |
|
|
Trastuzumab pamirtecan
|
BAT-0606 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
P1003 |
Mc-Gly-Gly-Phe-Gly |
|
|
ESG401
|
Anti-TROP2 IgG1 mAb |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
SN-38 |
A proprietary stable-cleavable linker |
|
|
Trastuzumab bultecan
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
NT1 |
PODS-CHX-A"-DTPA |
|
|
Rinatabart sesutecan
|
Rinatabart |
Folate receptor alpha (FOLR1) |
Exatecan |
T1000 |
|
|
Garetatug rezetecan
|
Garetatug |
Claudin-18.2 (CLDN18.2) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
Trastuzumab brengitecan
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ed-04 |
Gly-Mal-Gly-Gly-Phe-Gly |
|
|
FDA018
|
Anti-Trop-2 mAb |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
SN-38 |
An acid-cleavable linker |
|
|
Mocertatug rezetecan
|
Mocertatug |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
Risvutatug rezetecan
|
Risvutatug |
CD276 antigen (CD276) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
Arcotatug tavatecan
|
Anti-CLDN18.2 mAb |
Claudin-18.2 (CLDN18.2) |
Exatecan |
Synaffix linker |
|
|
Anbenitamab repodatecan
|
Anbenitamab |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4) |
DXd |
DBCO-PEG4-Mc-Gly-Gly-Phe-Gly |
|
|
Ruzaltatug rezetecan
|
Ruzaltatug |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
Notiretatug rezetecan
|
Anti-Nectin-4 antibody |
Nectin-4 (NECTIN4) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
Tambotatug pelitecan
|
Tambotatug |
CD276 antigen (CD276) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
SYS6010
|
Anti-EGFR antibody |
Epidermal growth factor receptor (EGFR) |
JS-1 |
Mc-Gly-Gly-Phe-Gly |
|
|
telisotuzumab adizutecan
|
Telisotuzumab |
Hepatocyte growth factor receptor (MET) |
AMDCPT |
Adizutecan linker |
Phase 3
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Tizetatug rezetecan
|
Tizetatug |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
TQB2102
|
Anti-HER2 antibody |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4) |
2-DDDX-d |
Mc-Gly-Gly-Phe-Gly |
|
|
HLX43
|
HLX20 |
Programmed cell death 1 ligand 1 (PD-L1) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
JSKN-016
|
Anti-HER3/TROP2 bsAb |
Receptor tyrosine-protein kinase erbB-3 (HER3); Tumor-associated calcium signal transducer 2 (TACSTD2) |
TOP1 inhibitor |
A cleavable linker |
Phase 2 (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Labetuzumab govitecan
|
Labetuzumab |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
SN-38 |
CL2A |
Phase 3
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
Puxitatug samrotecan
|
Puxitatug |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
AZ14170132 (AZ0132) |
Mal-PEG8-Val-Ala |
|
|
Sacituzumab drozuntecan
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
P1021 |
Mc-Gly-Gly-Phe-Gly |
|
|
MHB088C
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
MH30010008 |
A cleavable linker |
|
|
PRO1160
|
Anti-CD70 antibody |
CD70 antigen (CD70) |
Exatecan |
T1000 |
|
|
XNW27011
|
Anti-CLDN18.2 antibody |
Claudin-18.2 (CLDN18.2) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
Torvutatug samrotecan
|
Torvutatug |
Folate receptor alpha (FOLR1) |
AZ14170132 (AZ0132) |
Mal-PEG8-Val-Ala |
|
|
MHB036C
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
MH30010008 |
Stable cleavable linker |
|
|
BL-M02D1
|
hu4D3 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Ed-04 |
Cathepsin B cleavable linker |
|
|
Precemtabart tocentecan
|
Precemtabart |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Exatecan |
Mal-glucuronide-PABC |
|
|
SKB410
|
Anti-Nectin-4 antibody |
Nectin-4 (NECTIN4) |
TOP1 inhibitor |
Undisclosed |
|
|
TUB-030
|
Anti-5T4 antibody |
Trophoblast glycoprotein (TPBG) |
Exatecan |
P5 (PEG24)-Val-Cit-PABC |
|
|
9MW2921
[5]
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Mtoxin |
A cleavable linker |
|
|
TUB-040
|
Anti-Napi2b Fc-silenced IgG1 mAb |
Sodium-dependent phosphate transport protein 2B (SLC34A2) |
Exatecan |
P5 (PEG24)-Val-Cit-PABC |
|
|
GQ1010
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Camptothecin analog |
A cleavable open-ring linker |
|
|
OBI-992
|
R4702 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
Mal-PEG24-Val-Ala-PABC |
|
|
DS-3939
|
Gatipotuzumab |
Mucin-1 (MUC1) |
DXd |
Mc-Gly-Gly-Phe-Gly |
|
|
DB-1311
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
P1021 |
Mc-Gly-Gly-Phe-Gly |
|
|
DB-1310
|
Anti-HER3 IgG1 mAb |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
P1021 |
Mc-Gly-Gly-Phe-Gly |
|
|
DB-1419
|
Anti-B7H3/PDL1 bsAb |
CD276 antigen (CD276); Programmed cell death 1 ligand 1 (PD-L1) |
P1003 |
A tetra-peptide based cleavable linker |
|
|
PRO-1286
|
Anti-EGFR/c-Met bsAb |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
Exatecan |
T1000 |
|
|
Lixarkitug samrotecan
|
INT016 |
Interleukin-3 receptor subunit alpha (IL3RA) |
AZ14170132 (AZ0132) |
Mal-PEG8-Val-Ala |
|
|
YL205
|
Anti-NaPi2b mAb |
Sodium-dependent phosphate transport protein 2B (SLC34A2) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
AMT-253
|
Anti-MUC18 IgG1 mAb |
Cell surface glycoprotein MUC18 (MCAM) |
Exatecan |
T1000 |
|
|
AMT-116
|
Anti-CD44v9 antibody |
CD44v9 |
KL610023 |
Hydrolysable linker |
Phase 2
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
FDA022
[6]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DXd |
Mc-Val-Ala-PABC double self-immolative linker |
|
|
BAT8007
|
Anti-Nectin-4 antibody |
Nectin-4 (NECTIN4) |
Exatecan |
A cleavable but systemically stable linker |
|
|
BAT8008
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
Maleimide tetrapeptide-based cleavable linker |
|
|
BAT8006
|
Anti-FRα antibody |
Folate receptor alpha (FOLR1) |
Exatecan |
A cleavable linker |
|
|
BAT8009
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
Exatecan |
A cleavable linker |
|
|
BAT8010
|
Anti-HER2 antibody |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
A cleavable linker |
|
|
SHR-A1912
|
SHR-1920 |
B-cell antigen receptor complex-associated protein beta chain (CD79B) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
SKB315
|
Anti-CLDN18.2 antibody |
Claudin-18.2 (CLDN18.2) |
Belotecan-derivative |
Kthiol (pyrimidine-thiol) oligopeptide linker |
|
|
YL202
|
Anti-HER3 IgG1 mAb |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
Tilatamig samrotecan
|
Tilatamig |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
AZ14170132 (AZ0132) |
Mal-PEG8-Val-Ala |
|
|
TQB2103
|
Anti-CLDN18.2 IgG1 mAb |
Claudin-18.2 (CLDN18.2) |
2-DDDX-d |
A cleavable linker |
|
|
BL-M11D1
|
Gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
Ed-04 |
Gly-Mal-Gly-Gly-Phe-Gly |
|
|
FZ-AD004
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
DXd |
Mc-Val-Ala-PABC double self-immolative linker |
|
|
ZL-1310
[7]
|
Undisclosed |
Delta-like protein 3 (DLL3) |
YL0010014 |
Tumor microenviroment activable tripeptide linker |
|
|
BL-M08D1
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Ed-04 |
Gly-Mal-Gly-Gly-Phe-Gly |
|
|
BL-M05D1
|
5103F3 |
Claudin-18.2 (CLDN18.2) |
Ed-04 |
Gly-Mal-Gly-Gly-Phe-Gly |
|
|
HLX42
|
Anti-EGFR IgG1 mAb |
Epidermal growth factor receptor (EGFR) |
TOP1 inhibitor |
A cleavable linker |
|
|
PHN-010
|
Undisclosed |
Undisclosed |
TOP1 inhibitor |
Undisclosed |
|
|
AMT-676
|
Anti-CDH17 antibody |
Cadherin-17 (CDH17) |
Exatecan |
T1000 |
|
|
LY-4170156
|
Fc-silent FRalpha specific humanized IgG1 antibody |
Folate receptor alpha (FOLR1) |
Exatecan |
Mal-Polysarcosine10-Val-Ala-PABC |
|
|
HBM9033
|
Anti-MSLN antibody |
Mesothelin (MSLN) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
DXC006
|
DXA006 |
Neural cell adhesion molecule 1 (NCAM1) |
CPT113 |
A cleavable peptide linker |
|
|
BG-C9074
|
Anti-B7H4 antibody |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
TOP1 inhibitor |
A cleavable linker |
|
|
Varsetatug masetecan
|
Varsetatug |
Epithelial cell adhesion molecule (EPCAM) |
CAMP59 |
L-ala-ala-ala (TAL) |
|
|
DM002
|
Anti-HER3/Muc1 bsAb |
Receptor tyrosine-protein kinase erbB-3 (HER3); Mucin-1 (MUC1) |
BCPT02 |
Hydrophilic, protease-cleavable linker |
|
|
DM001
|
Anti-EGFR/TROP2 bsAb |
Epidermal growth factor receptor (EGFR); Tumor-associated calcium signal transducer 2 (TACSTD2) |
BCPT02 |
Hydrophilic, protease-cleavable linker |
|
|
AMT-707
|
A humanized anti-CDH6 IgG1 mAb |
Cadherin-6 (CDH6) |
Exatecan |
T1000 |
|
|
ZW191
|
Anti-FOLR1 IgG1 mAb |
Folate receptor alpha (FOLR1) |
ZD06519 |
Mc-Gly-Gly-Phe-Gly-AM |
|
|
ADRX-0405
|
Anti-STEAP1 antibody |
Metalloreductase STEAP1 (STEAP1) |
Undisclosed |
A cleavable linker |
|
|
DXC1002
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
CPT113 |
CrossConju linker |
|
|
AMT-562
|
Ab562 |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
Exatecan |
T800 |
|
|
SGN-CEACAM5C
|
Tusamitamab |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
AMDCPT |
A cleavable linker |
|
|
IBI3001
|
IBI-334 |
CD276 antigen; Epidermal growth factor receptor (EGFR) |
Exatecan |
Undisclosed |
|
|
IBI3005
|
Anti-EGFR/HER3 bsAb |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3) |
NT1 |
Undisclosed |
|
|
ABBV-969
|
Anti-PSMA/STEAP1 IgG1 mAb |
Glutamate carboxypeptidase 2 (FOLH1); Metalloreductase STEAP1 (STEAP1) |
A-1770637 |
BrAc-Val-Ala |
|
|
DM005
|
Anti-EGFR/c-Met bsAb |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
BCPT02 |
Hydrophilic, protease-cleavable linker |
|
|
Turmetabart adizutecan
|
Anti-SEZ6 antibody |
Seizure protein 6 homolog (SEZ6) |
A-1770637 |
BrAc-Val-Ala |
|
|
IPH45
|
Anti-Nectin-4 antibody |
Nectin-4 (NECTIN4) |
Exatecan |
A cleavable hydrophilic linker |
|
|
YL211
|
Anti-c-Met antibody |
Hepatocyte growth factor receptor (MET) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
LY4101174
|
Anti-Nectin-4 antibody |
Nectin-4 (NECTIN4) |
Exatecan |
maleimide-β-glucuronide poly-sarcosine linker |
|
|
LY4052031
|
Anti-Nectin-4 IgG1 Fc-silent mAb |
Nectin-4 (NECTIN4) |
LSN3889710 |
A cleavable peptide linker |
|
|
SHR-4849
|
SHR-2495 |
Delta-like protein 3 (DLL3) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
SHR-1826
|
A humanized anti-c-MET IgG2 mAb |
Hepatocyte growth factor receptor (MET) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
Phase 1 (discontinued)
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
DS-6157
|
Anti-GPR20 antibody |
G-protein coupled receptor 20 (GPR20) |
DXd |
Mc-Gly-Gly-Phe-Gly |
Phase 1/2
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
7MW3711
[8]
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
Mtoxin |
A cleavable linker |
|
|
CAC10-CPT-LB
[9]
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Methylenedioxy CPT2 (CPT2) |
Mc-PEG4-Val-Lys-Gly |
|
|
CAC10-CPT-LC
[9]
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Methylenedioxy CPT2 (CPT2) |
Mc-PEG8-Val-Lys-Gly |
|
|
H00-CPT-LC
[9]
|
Anti-CD30 mAb h00 |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Methylenedioxy CPT2 (CPT2) |
Mc-PEG8-Val-Lys-Gly |
|
|
CAC10-DT
[9]
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
CAC10-GT
[9]
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
Mil40-5
[10]
|
Mil40 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Mc-Val-Ala-PABC |
|
|
Mil40-6
[10]
|
Mil40 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Mal-PEG2-Val-Ala-PABC |
|
|
Mil40-7
[10]
|
Mil40 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Mal-PEG4-Val-Ala-PABC |
|
|
Mil40-8
[10]
|
Mil40 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Mal-PEG8-Val-Ala-PABC |
|
|
40H3-CL2A-SN38
[11]
|
Anti-EGFR mAb 40H3 |
Epidermal growth factor receptor (EGFR) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
40H3-Deruxtecan
[11]
|
Anti-EGFR mAb 40H3 |
Epidermal growth factor receptor (EGFR) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
Lmab-CL2A-SN38
[12]
|
Labetuzumab |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Active metabolite of irinotecan SN38 |
CL2E |
|
|
Emab-CL2E-SN38
[12]
|
Epratuzumab |
B-cell receptor CD22 (CD22) |
Active metabolite of irinotecan SN38 |
CL2E |
|
|
N501-SN38
[13]
|
Anti-5T4 n501 (nanobody) |
Trophoblast glycoprotein (TPBG) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
M603-SN38 DAR6
[13]
|
Anti-5T4 mAb m603 |
Trophoblast glycoprotein (TPBG) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
CAC10-CPT-LA
[9]
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Methylenedioxy CPT1 (CPT1) |
Mc-PEG4-Val-Lys-Gly |
|
|
H00-CPT-LA
[9]
|
Anti-CD30 mAb h00 |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Methylenedioxy CPT1 (CPT1) |
Mc-PEG4-Val-Lys-Gly |
|
|
H00-CPT-LB
[9]
|
Anti-CD30 mAb h00 |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Methylenedioxy CPT2 (CPT2) |
Mc-PEG4-Val-Lys-Gly |
|
|
H00-DT
[9]
|
Anti-CD30 mAb h00 |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H00-GT
[14]
|
Anti-CD30 mAb h00 |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
Zocilurtatug pelitecan
[15]
|
Zocilurtatug |
Delta-like protein 3 (DLL3) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
BL-M14D1
[16]
|
Anti-DLL3 mAb |
Delta-like protein 3 (DLL3) |
Ed-04 |
Gly-Mal-Gly-Gly-Phe-Gly |
|
|
HB0052
[17]
|
Anti-CD73 antibody |
Thymidylate 5'-phosphatase (NT5E) |
SN-38 |
A cleavable linker |
|
|
DXC-014
[18]
|
Anti-B7H3/PSMA bsAb |
CD276 antigen; Glutamate carboxypeptidase 2 (FOLH1) |
TOP1 inhibitor |
Undisclosed |
|
|
XB371
[19]
|
Anti-tissue factor antibody |
Tissue factor (F3) |
Belotecan |
A cleavable linker |
|
|
DpADC
[20]
|
Undisclosed |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Topo1 inhibitor+immune agonist |
Undisclosed |
|
|
HER2 targeted DEP conjugate
[21]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
VL-DAB31-SN38
[22]
|
Rabbit derived VL single-domain Anti-ody |
Undisclosed |
Active metabolite of irinotecan SN38 |
Mal-Cyc-PEG3-DAB |
|
|
ROS-responsive SN38 ADC
[22]
|
Rabbit derived VL single-domain Anti-ody |
Undisclosed |
Active metabolite of irinotecan SN38 |
Mal-Cyc-PEG3-DAB |
|
|
HLL1-CL2A-SN38
[23]
|
Milatuzumab |
HLA class II histocompatibility antigen gamma chain (CD74) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
Mil40-11 (DAR=7.1)
[10]
|
Mil40 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Mc-PEG8-Val-Ala-PABC |
|
|
Mil40-11 (DAR=3.8)
[10]
|
Mil40 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Mc-PEG8-Val-Ala-PABC |
|
|
M603-SN38 DAR8
[13]
|
Anti-5T4 mAb m603 |
Trophoblast glycoprotein (TPBG) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
M603-SN38 DAR4
[13]
|
Anti-5T4 mAb m603 |
Trophoblast glycoprotein (TPBG) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
IMMU-140
[24]
|
IMMU-114 |
HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
HPAM4-CL2A-SN38
[25]
|
Anti-MUC1 mAb hPAM4 |
Mucin-1 (MUC1) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
HA19-SN38 antibody-drug conjugate
[26]
|
Anti-CD19 mAb hA19 |
B-lymphocyte antigen CD19 (CD19) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
A7R-ADC-SN38
[27]
|
Anti-IL7R mAb A7R |
Interleukin-7 receptor subunit alpha (IL7R) |
Active metabolite of irinotecan SN38 |
Mal-PEG12-carbamate-PEG27 |
|
|
Raludotatug deruxtecan
[28]
|
Raludotatug |
Cadherin-6 (CDH6) |
DXd |
Mc-Gly-Gly-Phe-Gly |
|
|
SMP-190
[29]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Unique hydrophilic Linker |
|
|
PRO-1102
[30]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Cleavable hydrophilic linker |
|
|
Tra-Exa-PSAR10
[31]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mal-Exa-PSAR10 |
|
|
Tra-Exa-PSAR0
[31]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mal-Exa-PSAR0 |
|
|
STRO-003
[32]
|
SP11285 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
SC3417 |
|
|
HMBD-501
[33]
|
Anti-HER3 mAb |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
Exatecan |
A cleavable linker |
|
|
NV104
[34]
|
Undisclosed |
CD276 antigen (CD276) |
Irinotecan |
Undisclosed |
|
|
NV103
[35]
|
Undisclosed |
CD99 antigen (CD99) |
Irinotecan |
Undisclosed |
|
|
DAN-311
[36]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Camptothecin |
Undisclosed |
|
|
ZW251
[37]
|
Anti-GPC3 antibody |
Glypican-3 (GPC3) |
ZD06519 |
Mc-Gly-Gly-Phe-Gly-AM |
|
|
ZW-220
[38]
|
Fully humanized Anti-SLC34A2 IgG1 mAb |
Sodium-dependent phosphate transport protein 2B (SLC34A2) |
ZD06519 |
Mc-Gly-Gly-Phe-Gly-AM |
|
|
AMB-101
[39]
|
Undisclosed |
Undisclosed |
Topoisomerase I inhibitor |
Undisclosed |
|
|
STRO-004
[40]
|
Anti-tissue factor mAb |
Tissue factor (F3) |
Exatecan |
A cleavable linker |
|
|
SIBP-A13
[41]
|
Anti-HER3 mAb |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
DXd |
Mc-VASGFG |
|
|
Trastuzumab-L6
[42]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
MF-6 |
Bridged PEG4-valine-alanine |
|
|
Trastuzumab-T1000-exatecan
[43]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Cot-APTEDB-SN38
[44]
|
Anti-EDB Ab cot |
Vesicle-associated membrane protein 8 (VAMP8) |
Active metabolite of irinotecan SN38 |
Mal-PEG4-Ala |
|
|
ADC1-2
[45]
|
Cofetuzumab |
Inactive tyrosine-protein kinase 7 (PTK7) |
ADC 1-2 payload |
ADC 1-2 linker |
|
|
ADC1-4
[45]
|
Cofetuzumab |
Inactive tyrosine-protein kinase 7 (PTK7) |
ADC 1-4 payload |
ADC 1-4 linker |
|
|
ADC1-11
[45]
|
Cofetuzumab |
Inactive tyrosine-protein kinase 7 (PTK7) |
ADC 1-11 payload |
ADC 1-11 linker |
|
|
ADC2-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-2 payload |
ADC 2-2 linker |
|
|
ADC2-4
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-4 payload |
ADC 2-4 linker |
|
|
ADC2-6-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-6-2 payload |
ADC 2-6-2 linker |
|
|
ADC2-7-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-7-2 payload |
ADC 2-7-2 linker |
|
|
ADC2-9-1
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-9-1 payload |
ADC 2-9-1 linker |
|
|
ADC2-9-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-9-2 payload |
ADC 2-9-2 linker |
|
|
ADC2-10
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-10 payload |
ADC 2-10 linker |
|
|
ADC2-11
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-11 payload |
ADC 2-11 linker |
|
|
ADC2-22
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-22 payload |
ADC 2-22 linker |
|
|
ADC2-23
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-23 payload |
ADC 2-23 linker |
|
|
ADC2-24
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-24 payload |
ADC 2-24 linker |
|
|
ADC2-25
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-25 payload |
ADC 2-25 linker |
|
|
ADC2-26
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-26 payload |
ADC 2-26 linker |
|
|
ADC2-27
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-27 payload |
ADC 2-27 linker |
|
|
ADC2-29
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-29 payload |
ADC 2-29 linker |
|
|
ADC2-30
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-30 payload |
ADC 2-30 linker |
|
|
ADC2-31
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-31 payload |
ADC 2-31 linker |
|
|
ADC2-32
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-32 payload |
ADC 2-32 linker |
|
|
ADC2-33
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-33 payload |
ADC 2-33 linker |
|
|
ADC2-34
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-34 payload |
ADC 2-34 linker |
|
|
ADC2-35
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-35 payload |
ADC 2-35 linker |
|
|
ADC2-36-1
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-36-1 payload |
ADC 2-36-1 linker |
|
|
ADC2-36-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-36-2 payload |
ADC 2-36-2 linker |
|
|
ADC2-37
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-37 payload |
ADC 2-37 linker |
|
|
ADC2-38
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-38 payload |
ADC 2-38 linker |
|
|
ADC2-39
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-39 payload |
ADC 2-39 linker |
|
|
ADC2-40
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-40 payload |
ADC 2-40 linker |
|
|
ADC2-41
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-41 payload |
ADC 2-41 linker |
|
|
ADC2-42
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-42 payload |
ADC 2-42 linker |
|
|
ADC2-42-RO
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-42-RO payload |
ADC 2-42-RO linker |
|
|
ADC2-43
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-43 payload |
ADC 2-43 linker |
|
|
ADC2-44
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-44 payload |
ADC 2-44 linker |
|
|
ADC2-45
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-45 payload |
ADC 2-45 linker |
|
|
ADC2-46
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-46 payload |
ADC 2-46 linker |
|
|
ADC2-47
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-47 payload |
ADC 2-47 linker |
|
|
ADC2-48
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-48 payload |
ADC 2-48 linker |
|
|
ADC2-49
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-49 payload |
ADC 2-49 linker |
|
|
ADC2-50
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-50 payload |
ADC 2-50 linker |
|
|
ADC2-51
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-51 payload |
ADC 2-51 linker |
|
|
ADC2-53
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-53 payload |
ADC 2-53 linker |
|
|
ADC2-54
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-54 payload |
ADC 2-54 linker |
|
|
ADC2-55
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-55 payload |
ADC 2-55 linker |
|
|
ADC2-56
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-56 payload |
ADC 2-56 linker |
|
|
ADC2-57
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-57 payload |
ADC 2-57 linker |
|
|
ADC2-58
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-58 payload |
ADC 2-58 linker |
|
|
ADC2-59
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-59 payload |
ADC 2-59 linker |
|
|
ADC2-60
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-60 payload |
ADC 2-60 linker |
|
|
ADC2-61
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-61 payload |
ADC 2-61 linker |
|
|
ADC-2-62-1
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-62-1 payload |
ADC 2-62-1 linker |
|
|
ADC-2-62-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-62-2 payload |
ADC 2-62-2 linker |
|
|
ADC-2-63-1
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-63-1 payload |
ADC 2-63-1 linker |
|
|
ADC-2-63-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-63-2 payload |
ADC 2-63-2 linker |
|
|
ADC-2-64-1
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-64-1 payload |
ADC 2-64-1 linker |
|
|
ADC-2-64-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-64-2 payload |
ADC 2-64-2 linker |
|
|
ADC-2-65-1
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-65-1 payload |
ADC 2-65-1 linker |
|
|
ADC-2-65-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-65-2 payload |
ADC 2-65-2 linker |
|
|
ADC3-1
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 3-1 payload |
ADC 3-1 linker |
|
|
ADC3-2
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 3-2 payload |
ADC 3-2 linker |
|
|
ADC3-3
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 3-3 payload |
ADC 3-3 linker |
|
|
ADC3-4
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 3-4 payload |
ADC 3-4 linker |
|
|
ADC3-5
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 3-5 payload |
ADC 3-5 linker |
|
|
ADC3-6
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-6 payload |
ADC 3-6 linker |
|
|
ADC3-7
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-7 payload |
ADC 3-7 linker |
|
|
ADC3-8
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-8 payload |
ADC 3-8 linker |
|
|
ADC3-9
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-9 payload |
ADC 3-9 linker |
|
|
ADC3-10
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-10 payload |
ADC 3-10 linker |
|
|
ADC3-11
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-11 payload |
ADC 3-11 linker |
|
|
ADC3-12
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-12 payload |
ADC 3-12 linker |
|
|
ADC3-13
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-13 payload |
ADC 3-13 linker |
|
|
ADC3-14
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-14 payload |
ADC 3-14 linker |
|
|
ADC3-15
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-15 payload |
ADC 3-15 linker |
|
|
ADC3-16
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-16 payload |
ADC 3-16 linker |
|
|
ADC3-17
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-17 payload |
ADC 3-17 linker |
|
|
ADC3-18
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-18 payload |
ADC 3-18 linker |
|
|
ADC3-19
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-19 payload |
ADC 3-19 linker |
|
|
ADC3-20
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC 3-20 payload |
ADC 3-20 linker |
|
|
ADC-C2
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC-C2 payload |
ADC-C2 linker |
|
|
ADC-C3
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC-C3 payload |
ADC-C3 linker |
|
|
ADC-C4
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC-C4 payload |
ADC-C4 linker |
|
|
ADC-C5
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC-C5 payload |
ADC-C5 linker |
|
|
ADC1-1
[45]
|
Cofetuzumab |
Inactive tyrosine-protein kinase 7 (PTK7) |
ADC 1-1 payload |
ADC 1-1 linker |
|
|
ADC1-12
[45]
|
Cofetuzumab |
Inactive tyrosine-protein kinase 7 (PTK7) |
ADC 1-12 payload |
ADC 1-12 linker |
|
|
ADC2-A
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-A payload |
ADC 2-A linker |
|
|
ADC2-B
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-B payload |
ADC 2-B linker |
|
|
ADC2-12
[45]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
ADC 2-12 payload |
ADC 2-12 linker |
|
|
ADC-C1
[45]
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
ADC-C1 payload |
ADC-C1 linker |
|
|
Sacituzumab-Deruxtecan
[46]
|
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
WO2022078260A1 ADC-1
[47]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ln-D9 |
WO2022078260A1_ADC-1 linker |
|
|
WO2022078260A1 ADC-2
[47]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ln-D1 |
WO2022078260A1_ADC-2 linker |
|
|
WO2022078260A1 ADC-3
[47]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ln-D2 |
WO2022078260A1_ADC-3 linker |
|
|
WO2022078260A1 ADC-4
[47]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ln-D4 |
WO2022078260A1_ADC-4 linker |
|
|
WO2022078260A1 ADC-5
[47]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ln-D5 |
WO2022078260A1_ADC-5 linker |
|
|
WO2022078260A1 ADC-6
[47]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ln-D6 |
WO2022078260A1_ADC-6 linker |
|
|
WO2022078260A1 ADC-7
[47]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ln-D7 |
WO2022078260A1_ADC-7 linker |
|
|
WO2022078260A1 ADC-8
[47]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ln-D8 |
WO2022078260A1_ADC-8 linker |
|
|
WO2022078260A1 ADC-9
[47]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
Ln-D2 |
WO2022078260A1_ADC-9 linker |
|
|
WO2022078260A1 ADC-10
[47]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
Ln-D7 |
WO2022078260A1_ADC-10 linker |
|
|
Epratuzumab-CL2E-SN-38
[48]
|
Epratuzumab |
B-cell receptor CD22 (CD22) |
Active metabolite of irinotecan SN38 |
CL2E |
|
|
Epratuzumab-SN-38
[48]
|
Epratuzumab |
B-cell receptor CD22 (CD22) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
Veltuzumab-SN-38
[48]
|
Veltuzumab |
B-lymphocyte antigen CD20 (MS4A1) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
Veltuzumab-CL2E-SN-38
[48]
|
Veltuzumab |
B-lymphocyte antigen CD20 (MS4A1) |
Active metabolite of irinotecan SN38 |
CL2E |
|
|
Labetuzumab-CL2E-SN-38
[48]
|
Labetuzumab |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Active metabolite of irinotecan SN38 |
CL2E |
|
|
Labetuzumab-SN-38
[48]
|
Labetuzumab |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
Sacituzumab-SN-38
[48]
|
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
H01L02-DXd
[49]
|
Anti-CDH6 mAb H01L02 |
Cadherin-6 (CDH6) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H02L02-DXd
[49]
|
Anti-CDH6 mAb H02L02 |
Cadherin-6 (CDH6) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H02L03-DXd
[49]
|
Anti-CDH6 mAb H02L03 |
Cadherin-6 (CDH6) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H04L02-DXd
[49]
|
Anti-CDH6 mAb H04L02 |
Cadherin-6 (CDH6) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
NOV0712-DXd
[49]
|
Anti-CDH6 mAb NOV0712 |
Cadherin-6 (CDH6) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
IBI130
[50]
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
NT1 |
A cleavable linker |
Investigative
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
ZA202500202A D04-Y180F404/K42/E161-LP20
[51]
|
D04-Y180F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-4,4 nnAA-B-Glucuronide-PEG12 |
|
|
CBX-12
[52]
|
Undisclosed |
Undisclosed |
Exatecan |
Undisclosed |
|
|
Epratuzumab-SN38
[53]
|
Epratuzumab |
B-cell receptor CD22 (CD22) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
MTX-13
[54]
|
Ab13 |
Inactive tyrosine-protein kinase 7 (PTK7) |
Exatecan |
T1000 |
|
|
T-Ed9
[55]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ed9 |
Mc-Gly-Gly-Phe-Gly |
|
|
T-VEd9
[55]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ed9 |
Mc-Val-Ala |
|
|
CT109-SN-38
[56]
|
CT109 |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5); Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
38139459 8D302-DXd
[57]
|
8D302 |
Sortilin (SORT1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
Control to 8D302-DXd
[57]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
Control-DXd-DAR8
[58]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
hu1084-DXd-DAR3
[58]
|
Hu1084 |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
hu1084-DXd-DAR8
[58]
|
Hu1084 |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
aCEA5-iduronide-exatecan
[59]
|
huIgG1 LALA |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Exatecan |
MC-iduronide |
|
|
aCEA5-K (Ac)-exatecan
[59]
|
huIgG1 LALA |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Exatecan |
MC-K (Ac)VC |
|
|
aCEA5-AAN-exatecan
[59]
|
huIgG1 LALA |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Exatecan |
MC-AAN |
|
|
J87-Dxd
[60]
|
J87 |
T-cell antigen CD7 (CD7) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
39410752 ADC (7)
[61]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mal-Exo-EEVC |
|
|
39410752 ADC (9)
[61]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mal-Exo-EEVC |
|
|
Tras-Exa
[62]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
AB2 self-immolative dendritic scaffold |
|
|
Tras-Bel
[62]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Belotecan |
AB2 self-immolative dendritic scaffold |
|
|
SA-7-49
[63]
|
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
BVP-PEG-VC-PABC |
|
|
Fab-SN38
[64]
|
Anti-HER2 Fab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
LPETGGG-PEG3-Azide BCN-AVC |
|
|
DEVD ADC
[65]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
MC-DEVD-PAB |
|
|
CD66c-DXd
[66]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
bsSORT1×HER2-DXd
[67]
|
bsSORT1×HER2 |
Programmed cell death 1 ligand 1 (PD-L1) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
bsSORT1×CTRL-DXd
[67]
|
bsSORT1×CTRL |
Programmed cell death 1 ligand 1 (PD-L1) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
bsCTRL×HER2-DXd
[67]
|
bsCTRL×HER2 |
Programmed cell death 1 ligand 1 (PD-L1) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
Trastuzumab-DXd (38003245)
[67]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
SM001
[68]
|
Undisclosed |
Nectin-4 (NECTIN4) |
Exatecan |
Undisclosed |
|
|
SM002
[68]
|
Undisclosed |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
Undisclosed |
|
|
aPDL1-NPLG-SN38
[69]
|
Undisclosed |
Programmed cell death 1 ligand 1 (PD-L1) |
Active metabolite of irinotecan SN38 |
NPLG |
|
|
IgG-NPLG-SN38
[69]
|
Undisclosed |
Undisclosed |
Active metabolite of irinotecan SN38 |
NPLG |
|
|
37828728 ADC 1
[70]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
P5 (OEt)-VC-PAB |
|
|
37828728 ADC 2
[70]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
P5 (PEG2)-VC-PAB |
|
|
37828728 ADC 3
[70]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
P5 (PEG12)-VC-PAB |
|
|
37828728 ADC 4
[70]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
P5 (PEG12)-VA-PAB |
|
|
37828728 ADC 5
[70]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
P5 (PEG24)-VC-PAB |
|
|
37828728 ADC 6
[70]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mc-Val-Cit-PABC |
|
|
37828728 ADC 7
[70]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
P5 (PEG12)-VA |
|
|
37828728 ADC 8
[70]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
P5- (PEG12) |
|
|
38679234 ADC2
[71]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
40285886 7300-Deruxtecan
[72]
|
7300 |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
39757732 ADC4
[73]
|
Ab-2 |
Undisclosed |
DX-8951 derivative (DXd) |
D4 Linker |
|
|
40410803 16B10-Dxd
[74]
|
16B10 |
Transforming growth factor alpha (TGFA) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
40410803 5F1-Dxd
[74]
|
5F1 |
Transforming growth factor alpha (TGFA) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
39812376 84-SN38
[75]
|
#84.7 |
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
39812376 84-Dxd
[75]
|
#84.7 |
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
OncoFAP-GlyPro-Dxd
[76]
|
OncoFAP |
Prolyl endopeptidase FAP (FAP) |
DX-8951 derivative (DXd) |
Maleimido Caproyl-GlyPro-PAB linker |
|
|
ICAM-1-Dxd
[77]
|
Undisclosed |
Intercellular adhesion molecule 1 (ICAM1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
37520726 I1-DXd
[78]
|
Undisclosed |
Intercellular adhesion molecule 1 (ICAM1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
YB-800 Exatecan
[79]
|
YB-800 |
Neuronal pentraxin receptor (NPTXR) |
Exatecan |
Undisclosed |
|
|
OBI-902
[80]
|
Anti-TROP2 mAb |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
A cleavable linker |
|
|
MNC2-deruxtecan
[81]
|
huMNC2 |
Mucin-1 (MUC1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
Non-pH-B7-H3 Ab-Dxd
[82]
|
Non-pH-B7-H3 Ab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
pH-B7-H3 Ab-Dxd
[82]
|
pH-B7-H3 Ab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
TJ101
[83]
|
Anti-B7H3/EGFR bsAb |
CD276 antigen; Epidermal growth factor receptor (EGFR) |
PY-4car2 |
A cleavable linker |
|
|
ZL-6201
[84]
|
Anti-LRRC15 antibody |
Leucine-rich repeat-containing protein 15 (LRRC15) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
V66-Exatecan
[85]
|
V66 |
Extracellular DNA (ecDNA) |
Exatecan |
Undisclosed |
|
|
MHB042C
[86]
|
Anti-c-Met antibody |
Hepatocyte growth factor receptor (MET) |
MH30010008 |
Undisclosed |
|
|
LM-350
[87]
|
LM-150 |
Cadherin-17 (CDH17) |
LDX2 |
A cleavable linker |
|
|
DB-1418
[88]
|
Anti-EGFR/HER3 bsAb |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3) |
P1021 |
Mc-Gly-Gly-Phe-Gly |
|
|
PLB-001
[89]
|
Undisclosed |
Delta-like protein 3 (DLL3) |
Exatecan |
Undisclosed |
|
|
AZD0516
[90]
|
Anti-STEAP2 mAb |
Metalloreductase STEAP2 (STEAP2) |
Exatecan |
A cleavable linker |
|
|
BG-C137
[91]
|
Anti-FGFR2 antibody |
Fibroblast growth factor receptor 2 (FGFR2) |
TOP1 inhibitor |
A cleavable linker |
|
|
AMT-754
[92]
|
Ab-754 |
Tissue factor (F3) |
Exatecan |
T1000 |
|
|
MHB009C
[93]
|
Anti-B7H4 antibody |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
MH30010008 |
Undisclosed |
|
|
TD001
[94]
|
HuJ591 |
Glutamate carboxypeptidase 2 (FOLH1) |
Exatecan |
A cleavable linker |
|
|
LBL-054-Dxd
[95]
|
humanized CDH17 IgG1 monoclonal antibody |
Cadherin-17 (CDH17) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
YL242
[96]
|
Anti-VEGF antibody |
Vascular endothelial growth factor (VEGF) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
BGB-C354
[97]
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
TOP1 inhibitor |
A cleavable linker |
|
|
ADCE-017
[98]
|
Undisclosed |
C-type mannose receptor 2 (MRC2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
ADCE-202
[98]
|
Undisclosed |
C-type mannose receptor 2 (MRC2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
MHB048C
[99]
|
Anti-PSMA antibody |
Glutamate carboxypeptidase 2 (FOLH1) |
MH30010008 |
Undisclosed |
|
|
SOT109
[100]
|
Undisclosed |
Cadherin-17 (CDH17) |
Exatecan |
Undisclosed |
|
|
JSKN022
[101]
|
Anti-αvβ6/PDL1 bsAb |
Integrin beta-6 (ITGB6); Programmed cell death 1 ligand 1 (PD-L1) |
Alphatecan (T01) |
A cleavable linker |
|
|
SYS6041
[102]
|
Anti-FRα mAb |
Folate receptor alpha (FOLR1) |
Exatecan |
A cleavable linker |
|
|
3A11-Exatecan
[103]
|
3A11 |
Fibroblast growth factor receptor 4 (FGFR4) |
Exatecan |
mpGlyAsnAsn |
|
|
HuB14-VA-PL2202
[104]
|
Undisclosed |
Neutral amino acid transporter B(0) (SLC1A5) |
Exatecan |
Undisclosed |
|
|
PF-08046876
[105]
|
Sigvotatug |
Integrin beta-6 (ITGB6) |
AMDCPT |
Mal based β-glucuronide linker |
|
|
SYS6051
[106]
|
Undisclosed |
Tissue factor (F3) |
Exatecan |
Undisclosed |
|
|
HDM2017
[107]
|
Anti-CDH17 antibody |
Cadherin-17 (CDH17) |
CPT-derivative payloads |
Undisclosed |
|
|
BG-C477
[108]
|
Anti-CEA antibody |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
TOP1 inhibitor |
A cleavable linker |
|
|
ABBV-291
[109]
|
Anti-CD79b antibody |
B-cell antigen receptor complex-associated protein beta chain (CD79B) |
TOP1 inhibitor |
Undisclosed |
|
|
ACR246
[110]
|
Anti-5T4 humanized mAb |
Trophoblast glycoprotein (TPBG) |
D-2102 |
A cleavable linker |
|
|
Trastuzumab-Example 6
[111]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
CN119343152A Trastuzumab-Example6 Payload |
CN119343152A 1C1-Example1 Linker |
|
|
Trastuzumab-Example 7
[111]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
CN119343152A Trastuzumab-Example6 Payload |
CN119343152A Trastuzumab-Example7 Linker |
|
|
Trastuzumab-Example 8
[111]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119343152A Trastuzumab-Example8 Linker |
|
|
Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119343152A Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-K-P2/P4-P4-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P2/P8-P4-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P2/P8-P4-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P1/P2-P4-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P1/P1-P4-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P1-P4-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P2/P4-P1-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P2/P4-P1-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P2/P4-P2-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P2/P4-P2-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P1/P1-P1-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P1-P1-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P1/P1-P2-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P1-P2-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P1/P1-C2-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P1-C2-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P1/P2-C2-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P2-C2-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P1/P2-P1-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P2-P1-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-N-P1/P2-P1-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-N-P1/P2-P1-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-N-P1/P1-P1-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-N-P1/P1-P1-GGFG-Dxd Linker |
|
|
Trastuzumab-GDP-D-P2/P2-P2-GGFG-Dxd
[112]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Trastuzumab-GDP-D-P2/P2-P2-GGFG-Dxd Linker |
|
|
Rituximab-GDP-D-P1/P1-P1-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P1-P1-GGFG-Dxd Linker |
|
|
Rituximab-GDP-D-P2/P8-P4-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P2/P8-P4-GGFG-Dxd Linker |
|
|
Rituximab-GDP-D-P2/P4-P4-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd Linker |
|
|
Rituximab-GDP-D-P1/P1-P4-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P1-P4-GGFG-Dxd Linker |
|
|
Rituximab-GDP-D-P1/P1-P2-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P1-P2-GGFG-Dxd Linker |
|
|
Rituximab-GDP-D-P1/P1-C2-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-D-P1/P1-C2-GGFG-Dxd Linker |
|
|
Rituximab-GDP-D-P2/P2-P2-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
Trastuzumab-GDP-D-P2/P2-P2-GGFG-Dxd Linker |
|
|
Rituximab-GDP-N-P1/P1-P1-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
CN119326907A Trastuzumab-GDP-N-P1/P1-P1-GGFG-Dxd Linker |
|
|
Rituximab-GDP-K-P2/P4-P4-GGFG-Dxd
[112]
|
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
DX-8951 derivative (DXd) |
Trastuzumab-GDP-D-P2/P2-P2-GGFG-Dxd Linker |
|
|
aHer2- (AL6-LP1)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
aHer2- (AL6-LP15)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP15)n Linker |
|
|
aHer2- (AL6-LP13)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP13)n Linker |
|
|
aHer2- (AL7-LP1)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
FeID1- (AL7-LP1)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
aHer2- (AL7-LP13)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP13)n Linker |
|
|
FeID1- (AL7-LP13)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP13)n Linker |
|
|
aHer2- (AL7-LP5)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
CP1436 |
US20240269308A1 aHer2- (AL7-LP5)n Linker |
|
|
FeID1- (AL7-LP5)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
CP1436 |
US20240269308A1 aHer2- (AL7-LP5)n Linker |
|
|
aHer2- (AL7-LP12)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
CP1436 |
US20240269308A1 aHer2- (AL7-LP5)n Linker |
|
|
FeID1- (AL7-LP12)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
CP1436 |
US20240269308A1 aHer2- (AL7-LP5)n Linker |
|
|
aHer2- (AL7-LP5D)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
CP1436 |
US20240269308A1 aHer2- (AL7-LP5D)n Linker |
|
|
FeID1- (AL7-LP5D)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
CP1436 |
US20240269308A1 aHer2- (AL7-LP5D)n Linker |
|
|
aHer2- (AL4c-LP1B)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL4c-LP1B)n Linker |
|
|
FeID1- (AL4c-LP1B)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL4c-LP1B)n Linker |
|
|
aHer2- (AL4c-LP13C)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL4c-LP13C)n Linker |
|
|
FeID1- (AL4c-LP13C)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL4c-LP13C)n Linker |
|
|
aHer2- (AL11a-LP1)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
FeID1- (AL11a-LP1)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
aHer2- (AL11a-LP13)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP13)n Linker |
|
|
FeID1- (AL11a-LP13)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP13)n Linker |
|
|
aHer2- (AL11a-LP15)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP15)n Linker |
|
|
FeID1- (AL11a-LP15)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP15)n Linker |
|
|
aHer2- (BL1-LP1)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
FeID1- (BL1-LP1)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
aHer2- (BL1-LP13)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP13)n Linker |
|
|
FeID1- (BL1-LP13)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP13)n Linker |
|
|
aHer2- (BL3b-LP1)n
[113]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
FeID1- (BL3b-LP1)n
[113]
|
FeID1 |
DNA-binding protein inhibitor ID-1 (ID1) |
DX-8951 derivative (DXd) |
US20240269308A1 aHer2- (AL6-LP1)n Linker |
|
|
LN488-04-2
[114]
|
BY016 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
US20240269308A1 LN488-04-2 Linker |
|
|
LN488-01-1
[114]
|
BY016 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
US20240269308A1 LN488-01-1 Linker |
|
|
LN488-02-2
[114]
|
BY016 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
US20240269308A1 LN488-02-2 Linker |
|
|
LN488-05-2
[114]
|
BY016 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
US20240269308A1 LN488-05-2 Linker |
|
|
LN488-01-2
[114]
|
BY016 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
CN117616052A Antibody A-ADC1
[115]
|
Antibody A |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
DX-8951 derivative (DXd) |
DBCO-PEG4-GGFG-aminol |
|
|
CN115969996A ADC1
[116]
|
Antibody V3 |
CD276 antigen (CD276) |
Exatecan |
CB07 linker |
|
|
CN115969996A ADC2
[116]
|
Antibody V3 |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
CN115969996A ADC3
[116]
|
Antibody V3 |
CD276 antigen (CD276) |
Exatecan |
CB07 linker |
|
|
AU2023226367A1-2
[117]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
U-030 |
RU20241285-1-linker |
|
|
AU2023226367A1-11
[117]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
RU20241285-10-linker |
|
|
AU2023226367A1-12
[117]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
RU20241285-12-linker |
|
|
AU2023226367A1-13
[117]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
RU20241285-13-linker |
|
|
AU2023226367A1-20
[117]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor A |
EP4487874A1-13linker |
|
|
AU2023226367A1-23
[117]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
RU20241285-23-payload |
RU20241285-23-linker |
|
|
AU2023226367A1-24
[117]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
RU20241285-23-payload |
RU20241285-24-linker |
|
|
ZA202500202A 2188-D04-Y180/F404/K42/E161-LP1
[51]
|
2188-D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-L-cysteic acid-PEG4-VKG |
|
|
ZA202500202A 2188-D04-Y180/F404-LP10
[51]
|
2188-D04-Y180/F404 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
DX-8951 derivative (DXd) |
DBCO-PEG4-GGFG-aminol |
|
|
ZA202500202A 2188-D04-Y180/F404/K42/E161-LP10
[51]
|
2188-D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
DX-8951 derivative (DXd) |
DBCO-PEG4-GGFG-aminol |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP2
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-L-cysteic acid-PEG4-VKG |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP3 8
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-beta-Glucuronide-PEG12 |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP4 (8)
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP7
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nAA-PEG13-VKG |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP5
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-AAN |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP6
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-AAA |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP4 (7.52)
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
ZA202500202A D04-F404-LP14
[51]
|
D04-F404 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6,4 nnAA-PEG-VKG |
|
|
ZA202500202A D04-Y180F404/K42/E161-LP14
[51]
|
D04-Y180F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6,4 nnAA-PEG-VKG |
|
|
ZA202500202A D04-Y180F404/K42/E161-LP15
[51]
|
D04-Y180F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-4,6 nnAA-PEG-VKG |
|
|
ZA202500202A D04-Y180F404/K42/E161-LP17
[51]
|
D04-Y180F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-bridged nnAA-PEG-VKG |
|
|
ZA202500202A D04-Y180F404/K42/E161-LP18
[51]
|
D04-Y180F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6,6 nnAA-B-Glucuronide-PEG12 |
|
|
ZA202500202A D04-Y180F404/K42/E161-LP19
[51]
|
D04-Y180F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6,4 nnAA-B-Glucuronide-PEG12 |
|
|
ZA202500202A D04-Y180F404/K42/E161-LP4
[51]
|
D04-Y180F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
ZA202500202A D04-Y180/F241/F404/K42-LP3
[51]
|
D04-Y180/F241/F404/K42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-beta-Glucuronide-PEG12 |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP3 7.46
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-beta-Glucuronide-PEG12 |
|
|
ZA202500202A D04-Y180/F241/F404/K42-LP4
[51]
|
D04-Y180/F241/F404/K42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
ZA202500202A D04-Y180/F404/K42/E161-LP4
[51]
|
D04-Y180/F404/K42/E161 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
ZA202500202A AGFP-Y180/F241/F404/K42-LP3
[51]
|
AGFP-Y180/F241/F404/K42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-beta-Glucuronide-PEG12 |
|
|
ZA202500202A AGFP-Y180/F241/F404/K42-LP4
[51]
|
AGFP-Y180/F241/F404/K42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
FS001-VH3-VL2-Dxd
[118]
|
FS001-huVH3-huVL2 |
Glypican-3 (GPC3) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
FS001-VH4-VL3-Dxd
[118]
|
FS001-huVH4-huVL3 |
Glypican-3 (GPC3) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
WO2024193682A1 32G1-8D9-CPT2
[119]
|
Undisclosed |
Trophoblast glycoprotein (TPBG) |
CPT2 |
Undisclosed |
|
|
WO2024193682A1 32G1-8H10-CPT2
[119]
|
Undisclosed |
Trophoblast glycoprotein (TPBG) |
CPT2 |
Undisclosed |
|
|
WO2024193682A1 32G1-2F11-CPT2
[119]
|
Undisclosed |
Trophoblast glycoprotein (TPBG) |
CPT2 |
Undisclosed |
|
|
PF06263507-CPT2
[119]
|
Undisclosed |
Trophoblast glycoprotein (TPBG) |
CPT2 |
Undisclosed |
|
|
SYD-1875-CPT2
[119]
|
Undisclosed |
Trophoblast glycoprotein (TPBG) |
CPT2 |
Undisclosed |
|
|
Telisotuzumab-CPT2
[119]
|
Undisclosed |
Trophoblast glycoprotein (TPBG) |
CPT2 |
Undisclosed |
|
|
WO2024193682A1 32G1-CPT2
[119]
|
Undisclosed |
Trophoblast glycoprotein (TPBG) |
CPT2 |
Undisclosed |
|
|
WO2024193682A1 2F11-CPT2
[119]
|
Undisclosed |
Trophoblast glycoprotein (TPBG) |
CPT2 |
Undisclosed |
|
|
RKAAR-PABC-Exa
[120]
|
RKAAR |
Undisclosed |
Exatecan |
Mc-Val-Cit-PABC |
|
|
RRK-PABC-Exa
[120]
|
RRK |
Undisclosed |
Exatecan |
Mc-Val-Cit-PABC |
|
|
HK-PABC-Exa
[120]
|
HK |
Undisclosed |
Exatecan |
Mc-Val-Cit-PABC |
|
|
AHK-PABC-Exa
[120]
|
AHK |
Undisclosed |
Exatecan |
Mc-Val-Cit-PABC |
|
|
HKA-PABC-Exa
[120]
|
HKA |
Undisclosed |
Exatecan |
Mc-Val-Cit-PABC |
|
|
WO2024140927A1-ADC-D (DAR6)
[121]
|
mAb-A |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
WO2024140927A1-ADC-D (DAR2)
[121]
|
mAb-A |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
WO2024140927A1-ADC-F (DAR2)
[121]
|
mAb-D |
Vascular endothelial growth factor A (VEGFA) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
WO2024140927A1-ADC-H (DAR2)
[121]
|
mAb-E |
B-lymphocyte antigen CD20 (MS4A1) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
WO2024092067A1 2E7-deruxtecan
[122]
|
20000000 |
CD70 antigen (CD70) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
Ab[AL- LP1] 4
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL- LP2] 4
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL- LP3] 4
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL- LP4] 4
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL- LP8] 4
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL- LP9] 4
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL- LP3]
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL- LP8]
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL- LP9]
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
Ab[AL2- LP1] 4
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
Ab[AL2- LP17]n
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
Ab[AL2- LP17]
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
JP2025502147A ADC5
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
JP2025502147A ADC6
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
JP2025502147A ADC7
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
JP2025502147A ADC8
[123]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
KR1020250012631A+ADC
[124]
|
Undisclosed |
Cadherin-6 (CDH6) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
IN202417103159A 2188-IN202417103159A D04-Yl80/F404-LP10
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
DX-8951 derivative (DXd) |
DBCO-PEG4-GGFG-aminol |
|
|
IN202417103159A 2188-IN202417103159A D04-Yl80/F404/K42/E161 LP10
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
DX-8951 derivative (DXd) |
DBCO-PEG4-GGFG-aminol |
|
|
IN202417103159A D04-Y180/F404/K42/E161-LP2
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-L-cysteic acid-PEG4-VKG |
|
|
IN202417103159A D04-Y180/F404/K42/E161-LP3
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-beta-Glucuronide-PEG12 |
|
|
IN202417103159A D04-Y180/F404/K42/E161-LP4
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
IN202417103159A D04-Y180/F404/K42/E161-LP7
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nAA-PEG13-VKG |
|
|
IN202417103159A D04-Y180/F404/K42/E161-LP5
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-AAN |
|
|
IN202417103159A D04-Y180/F404/K42/E161-LP6
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-AAA |
|
|
IN202417103159A D04-Yl80/F404/K42/E161-LP4 7.52
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
IN202417103159A D04-F404-LP14
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6,4 nnAA-PEG-VKG |
|
|
IN202417103159A D04-Yl80F404/K42/E161-LP14
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6,4 nnAA-PEG-VKG |
|
|
IN202417103159A D04-Yl80F404/K42/E161- LP15
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-4,6 nnAA-PEG-VKG |
|
|
IN202417103159A D04-Yl80F404/K42/E161-LP17
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-bridged nnAA-PEG-VKG |
|
|
IN202417103159A D04-Yl80F404/K42/E161-LP18
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
Undisclosed |
|
|
IN202417103159A D04-Yl80F404/K42/E161-LP19
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
Undisclosed |
|
|
IN202417103159A D04-Yl80F404/K42/E161-LP20
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
Undisclosed |
|
|
IN202417103159A D04-Yl80/F241/F404/K42-LP3
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-beta-Glucuronide-PEG12 |
|
|
IN202417103159A D04-Yl80/F404/K42/E161-LP3
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-beta-Glucuronide-PEG12 |
|
|
IN202417103159A D04-Yl80/F241/F404/K42-LP4
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
IN202417103159A D04-Yl80/F404/K42/E161-LP4 8
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
IN202417103159A aGFP-Y180/F241/F404/K42-LP3
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-beta-Glucuronide-PEG12 |
|
|
IN202417103159A aGFP-Y180/F241/F404/K42-LP4
[125]
|
Undisclosed |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-VKG |
|
|
Tra-25-4
[126]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBX-7014 |
Mc-Gly-Gly-Phe-Gly |
|
|
Tra-25-6
[126]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBX-7016 |
Mc-Gly-Gly-Phe-Gly |
|
|
WBP301088-X2
[127]
|
Anti-b7h3 |
CD276 antigen (CD276) |
Topo1 inhibitor F |
Mc-Gly-Gly-Phe-Gly |
|
|
SG11202408662TA ADC-C1
[128]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
HER2-Dxd
[129]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Undisclosed |
|
|
IN202417078684A+ADC7
[130]
|
IN202417078684A+Ab4 |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
IN202417078684A+ADC8
[130]
|
IN202417078684A+Ab4 |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
IN202417078684A+ADC10
[130]
|
IN202417078684A+Ab4 |
Undisclosed |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
WO2023124537A1+ADC1
[131]
|
Anti-EGFR mAb |
Epidermal growth factor receptor (EGFR) |
Active metabolite of irinotecan SN38 |
DBCO-VC-PAB |
|
|
WO2023124537A1+ADC2
[131]
|
Anti-EGFR mAb |
Epidermal growth factor receptor (EGFR) |
Active metabolite of irinotecan SN38 |
DBCO-VC-PAB |
|
|
WO2023124537A1+ADC3
[131]
|
Anti-EGFR mAb |
Epidermal growth factor receptor (EGFR) |
Active metabolite of irinotecan SN38 |
DBCO-VC-PAB |
|
|
US20240245795A1 Antibody Conjugate 1
[132]
|
trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mc-Val-Cit-PABC |
|
|
US20240245795A1 Antibody Conjugate 5
[132]
|
trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
US20240245795A1 Antibody Conjugate 6
[132]
|
trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Undisclosed |
|
|
US20240245795A1 Antibody Conjugate 7
[132]
|
trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Antibody Conjugate 7 +Payload |
Undisclosed |
|
|
US20240245795A1 Antibody Conjugate 10
[132]
|
H01L02 |
Cadherin-6 (CDH6) |
Exatecan |
Undisclosed |
|
|
US20240245795A1 Antibody Conjugate 13
[132]
|
hRS7 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
Undisclosed |
|
|
US20240245795A1 Antibody Conjugate 14
[132]
|
hRS7 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
Undisclosed |
|
|
US20240245795A1 Antibody Conjugate 15
[132]
|
hRS7 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Antibody Conjugate 7 +Payload |
Undisclosed |
|
|
CN112341521B+ADC-3
[133]
|
Nimotuzumab |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
Camptothecin |
CN112341521B+Linker3 |
|
|
CN112341521B+ADC-4
[133]
|
Nimotuzumab |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
Camptothecin |
Undisclosed |
|
|
CN112341521B+ADC-5
[133]
|
Nimotuzumab |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
Topo1 inhibitor D |
CN112341521B+Linker3 |
|
|
CN112341521B+ADC-6
[133]
|
Nimotuzumab |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
Topo1 inhibitor D |
Undisclosed |
|
|
CN112341521B+ADC-7
[133]
|
Nimotuzumab |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
Topo1 inhibitor D |
Undisclosed |
|
|
CN112341521B+ADC-11
[133]
|
Nimotuzumab |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
CN112341521B+Payload11 |
CN112341521B+Linker11 |
|
|
CN112341521B+ADC-12
[133]
|
Nimotuzumab |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) |
CN112341521B+Payload11 |
CN112341521B+Linker12 |
|
|
AU2023306656A1 ADC3
[134]
|
Undisclosed |
CUB domain-containing protein 1 (CDCP1) |
Exatecan |
AU2023306656A1 ADC3 linker |
|
|
AU2023306656A1 ADC4
[134]
|
Undisclosed |
CUB domain-containing protein 1 (CDCP1) |
Exatecan |
AU2023306656A1 ADC3 linker |
|
|
EP4494658A1 antibody-drug conjugate 1
[135]
|
900698 |
Thymidylate 5'-phosphatase (NT5E) |
EP4494658A1 antibody-drug conjugate 1 payload |
EP4494658A1 antibody-drug conjugate 1 |
|
|
EP4494658A1 antibody-drug conjugate 2
[135]
|
900698 |
Thymidylate 5'-phosphatase (NT5E) |
EP4494658A1 antibody-drug conjugate 1 payload |
EP4494658A1 antibody-drug conjugate 2 |
|
|
PnakoMab-ADC
[136]
|
PankoMab |
Mucin-1 (MUC1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
PM-N54Q-ADC
[136]
|
PM-N54Q |
Mucin-1 (MUC1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
EP4471061A1 17c10_MC-Dxd
[137]
|
huASCT2 17c10 mAb |
Amino acid transporter (ASCT2) |
DX-8951 derivative (DXd) |
6-Maleimidocaproic acid |
|
|
ICT_MC-Dxd (Isotype control)
[137]
|
huASCT2 17c10 mAb |
Amino acid transporter (ASCT2) |
DX-8951 derivative (DXd) |
6-Maleimidocaproic acid |
|
|
EP4471061A1 MC_Dxd
[137]
|
huASCT2 17c10 mAb |
Amino acid transporter (ASCT2) |
DX-8951 derivative (DXd) |
6-Maleimidocaproic acid |
|
|
WO2024110905A1 ADC2-10
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Exatecan |
Linker of ADC2-10 |
|
|
WO2024110905A1 ADC2-27
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC2-27 |
|
|
WO2024110905A1 ADC2-38
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC2-38 |
|
|
WO2024110905A1 ADC2-49
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC2-49 |
|
|
WO2024110905A1 ADC2-58
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC2-58 |
|
|
WO2024110905A1 ADC2-61
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC2-61 |
|
|
WO2024110905A1 ADC3-7
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC2-49 |
|
|
WO2024110905A1 ADC3-12
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC2-58 |
|
|
WO2024110905A1 ADC3-15
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC2-61 |
|
|
WO2024110905A1 ADC3-16
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC3-16 |
|
|
WO2024110905A1 ADC3-17
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Linker of ADC3-16 |
|
|
WO2024110905A1 ADC3-18
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Mc-Val-Ala |
|
|
WO2024110905A1 ADC-1 BGB-C-81
[138]
|
Undisclosed |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
BGA2588
[138]
|
BGA5384 |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
aHer2- (AL6-LP13D)6.2
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
aHer2- (AL6-LP13D)6.2 Linker |
|
|
aHer2- (AL7-LP3)3.88
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
aHer2- (AL7-LP2)3.83 Linker |
|
|
FelD1- (AL7-LP3)3.82
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
aHer2- (AL7-LP2)3.83 Linker |
|
|
aHer2- (AL7-LP4)3.84
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
aHer2- (AL7-LP2)3.83 Linker |
|
|
FelD1- (AL7-LP4)3.82
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
aHer2- (AL7-LP2)3.83 Linker |
|
|
aHer2- (AL11a-LP15)7.6
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
aHer2- (AL11a-LP15)7.6 Linker |
|
|
FelD1- (AL11a-LP15)7.0
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
aHer2- (AL11a-LP15)7.6 Linker |
|
|
aHer2 1- (Mc-GGFG-DXD)7.7
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
aHer2 2- (Mc-GGFG-DXD)7.7
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
aHer2 3- (Mc-GGFG-DXD)7.7
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
FelD1 1- (Mc-GGFG-DXD)7.5
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
FelD1 2- (Mc-GGFG-DXD)7.5
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
FelD1 3- (Mc-GGFG-DXD)7.5
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
aHer2 1- (Mc-GGFG-DXD)7.1
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
aHer2 2- (Mc-GGFG-DXD)7.1
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
aHer2 3- (Mc-GGFG-DXD)7.1
[139]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
FelD1 1- (Mc-GGFG-DXD)7.0
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
FelD1 2- (Mc-GGFG-DXD)7.0
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
FelD1 3- (Mc-GGFG-DXD)7.0
[139]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
YC1613
[140]
|
J591 |
Glutamate carboxypeptidase 2 (FOLH1) |
Active metabolite of irinotecan SN38 |
Ab-MC-VC-PAB-DMEDA-PEG (N3)-SN38 Linker |
|
|
YC1628
[140]
|
J591 |
Glutamate carboxypeptidase 2 (FOLH1) |
Active metabolite of irinotecan SN38 |
Ab-MP2-VC-PAB-DMEDA-PEG (N3)-SN38 Linker |
|
|
YC1663
[140]
|
J591 |
Glutamate carboxypeptidase 2 (FOLH1) |
Active metabolite of irinotecan SN38 |
Ab-MC-MMAF-VC-PAB-DMEDA-PEG (N3)-SN38 Linker |
|
|
WO2024105206A1 16i-5657 2
[141]
|
TPP-5657 |
Undisclosed |
Mdo-cpt |
16i-5657 Linker |
|
|
WO2024105206A1 19i-5657 2
[141]
|
TPP-5657 |
Undisclosed |
Mdo-cpt |
6i-5657 Linker |
|
|
WO2024105206A1 23i-5657 2
[141]
|
TPP-5657 |
Undisclosed |
Mdo-cpt |
23i-5657 Linker |
|
|
WO2024105206A1 23p-Avelu 2
[141]
|
Avelumab |
Programmed cell death 1 ligand 1 (PD-L1) |
Mdo-cpt |
23i-5657 Linker |
|
|
WO2024105206A1 27i-5657 2
[141]
|
TPP-5657 |
Undisclosed |
Mdo-cpt |
22i-5657 Linker |
|
|
WO2024105206A1 28i-5657 2
[141]
|
TPP-5657 |
Undisclosed |
Mdo-cpt |
6i-5657 Linker |
|
|
WO2024105206A1 29p-Avelu 2
[141]
|
TPP-Avelumab |
Programmed cell death 1 ligand 1 (PD-L1) |
Mdo-cpt |
29p-Avelu Linker |
|
|
WO2024105206A1 32p-Avelu 2
[141]
|
TPP-Avelumab |
Programmed cell death 1 ligand 1 (PD-L1) |
Mdo-cpt |
32p-Avelu Linker |
|
|
WO2024105206A1 32e-1015 2
[141]
|
TPP-1015 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Mdo-cpt |
32p-Avelu Linker |
|
|
WO2024105206A1 36p-Avelu 2
[141]
|
TPP-Avelumab |
Programmed cell death 1 ligand 1 (PD-L1) |
Camptothecin |
36p-Avelu Linker |
|
|
WO2024105206A1 40p-Avelu 2
[141]
|
TPP-Avelumab |
Programmed cell death 1 ligand 1 (PD-L1) |
Camptothecin |
40i-5657 Linker |
|
|
AU2017341000B2 ADC (1)
[142]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H01L02-Dxd
[143]
|
H01L02 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H02L02-Dxd
[143]
|
H02L02 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H02L03-Dxd
[143]
|
H02L03 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H04L02-Dxd
[143]
|
H04L02 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
NOV0712-Dxd
[143]
|
NOV0712 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
H01L02-ADC
[144]
|
Anti-CDH6 mAb H01L02 |
Cadherin-6 (CDH6) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
IL317340A-8
[145]
|
Undisclosed |
CD276 antigen (CD276) |
Topo1 inhibitor F |
Mc-Gly-Gly-Phe-Gly |
|
|
WO2024231224A2 ADC-AFI-DXd
[146]
|
mAb_v64 |
Tumor-associated carbohydrate antigen sialyl-Tn (STn) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (5)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
HK40112172A+Antibody-drug conjugate (4)+Linker |
|
|
HK40112172A Antibody-drug conjugate (6)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
HK40112172A+Antibody-drug conjugate (6)+Linker |
|
|
HK40112172A Antibody-drug conjugate (7)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
HK40112172A+Antibody-drug conjugate (7)+Linker |
|
|
HK40112172A Antibody-drug conjugate (8)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
HK40112172A+Antibody-drug conjugate (7)+Linker |
|
|
HK40112172A Antibody-drug conjugate (9)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
HK40112172A+Antibody-drug conjugate (7)+Linker |
|
|
HK40112172A Antibody-drug conjugate (10)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
HK40112172A+Antibody-drug conjugate (7)+Linker |
|
|
HK40112172A Antibody-drug conjugate (12)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC13 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (13)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC13 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (15)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC13 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (16)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC13 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (21)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
HK40112172A+Antibody-drug conjugate (7)+Linker |
|
|
HK40112172A Antibody-drug conjugate (22)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
HK40112172A+Antibody-drug conjugate (7)+Linker |
|
|
HK40112172A Antibody-drug conjugate (24)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC25 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (25)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC25 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (26)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (27)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (28)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (29)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (30)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (31)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (36)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
SCHEMBL17022441 |
|
|
HK40112172A Antibody-drug conjugate (37)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
SCHEMBL17022441 |
|
|
HK40112172A Antibody-drug conjugate (41)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor B |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (42)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor B |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (43)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
HK40112172A+Antibody-drug conjugate (43)+Linker |
|
|
HK40112172A Antibody-drug conjugate (44)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
HK40112172A+Antibody-drug conjugate (44)+Linker |
|
|
HK40112172A Antibody-drug conjugate (46)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (47)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (48)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
HK40112172A Antibody-drug conjugate (49)
[147]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
mAb1-DXd
[148]
|
mAb1 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
mAb2-DXd
[148]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
mAb3-DXd
[148]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
mAb17-DXd
[148]
|
Undisclosed |
Undisclosed |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
mAb1-Extecan
[148]
|
mAb1 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mc-Gly-Gly-Phe-Gly |
|
|
CD44-DRT
[149]
|
Undisclosed |
CD44 antigen (CD44) |
DX-8951 derivative (DXd) |
CN117362435A+CD44-DRT+Linker |
|
|
CD44-SN-38
[149]
|
Undisclosed |
CD44 antigen (CD44) |
Active metabolite of irinotecan SN38 |
CN117362435A+CD44-SN-38+Linker |
|
|
Isumab01-C4
[150]
|
Undisclosed |
Folate receptor alpha (FOLR1) |
compound 4 |
Undisclosed |
|
|
Isumab01-C5
[150]
|
Undisclosed |
Folate receptor alpha (FOLR1) |
compound 5 |
Undisclosed |
|
|
Isumab04-C5
[150]
|
Undisclosed |
Undisclosed |
compound 5 |
Undisclosed |
|
|
WO2024140449A1 ADC5
[151]
|
HS627 |
Undisclosed |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC5+Linker |
|
|
WO2024140449A1 ADC6
[151]
|
IP140B |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC5+Linker |
|
|
WO2024140449A1 ADC7
[151]
|
HS627 |
Undisclosed |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC7+Linker |
|
|
WO2024140449A1 ADC8
[151]
|
IP140B |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC7+Linker |
|
|
WO2024140449A1 ADC9
[151]
|
HS627 |
Undisclosed |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC9+Linker |
|
|
WO2024140449A1 ADC10
[151]
|
IP140B |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC9+Linker |
|
|
WO2024140449A1 ADC11
[151]
|
HS627 |
Undisclosed |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC9+Linker |
|
|
WO2024140449A1 ADC12
[151]
|
IP140B |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC9+Linker |
|
|
WO2024140449A1 ADC21
[151]
|
HS627 |
Undisclosed |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC5+Linker |
|
|
WO2024140449A1 ADC22
[151]
|
IP140B |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2024140449A1+ADC5+payload |
WO2024140449A1+ADC5+Linker |
|
|
DiS-Compound -145
[152]
|
Undisclosed |
Undisclosed |
FD6 |
TW202426058A+DiS-Compound -145+Linker |
|
|
MT-GGFG-Compound140
[152]
|
Undisclosed |
Undisclosed |
10NH2-11F-Camptothecin |
CN115160403A+B17+Linker |
|
|
MT-GGFG-Compound141
[152]
|
Undisclosed |
Undisclosed |
FD5 |
CN115160403A+B17+Linker |
|
|
MT-GGFG-Compound145
[152]
|
Undisclosed |
Undisclosed |
FD5 |
CN115160403A+B17+Linker |
|
|
MT-GGFG-Compound148
[152]
|
Undisclosed |
Undisclosed |
FD7 |
CN115160403A+B17+Linker |
|
|
NHC-C-VA-Compound140
[152]
|
Undisclosed |
Undisclosed |
10NH2-11F-Camptothecin |
TW202426058A+NHC-C--VA-Compound140+Linker |
|
|
Trastuzumab-DXD (EP4183421A1)
[153]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
EP4183421A1+Trastuzumab-DXD+Linker |
|
|
Trastuzumab-DDDXD
[153]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
EP4183421A1+Trastuzumab-DDDXD+Linker |
|
|
EP4183421A1 23C2 Her2-2-DXD
[153]
|
23C2 Her2-2 |
Undisclosed |
Exatecan |
EP4183421A1+Trastuzumab-DXD+Linker |
|
|
EP4183421A1 23C2 Her2-2-DDDXD
[153]
|
23C2 Her2-2 |
Undisclosed |
Exatecan |
EP4183421A1+Trastuzumab-DDDXD+Linker |
|
|
CN115160403A B1
[154]
|
Undisclosed |
Undisclosed |
CN115160403A+B1+payload |
Mc-Gly-Gly-Phe-Gly |
|
|
CN115160403A B7
[154]
|
Undisclosed |
Undisclosed |
CN115160403A+B7+payload |
Mc-Gly-Gly-Phe-Gly |
|
|
CN115160403A B13
[154]
|
Undisclosed |
Undisclosed |
(4-NH2)-Exatecan |
CN115160403A+B11+Linker |
|
|
CN115160403A B14
[154]
|
Undisclosed |
Undisclosed |
CN115160403A+B1+payload |
CN115160403A+B14+Linker |
|
|
CN115160403A B15
[154]
|
Undisclosed |
Undisclosed |
CN115160403A+B1+payload |
CN115160403A+B15+Linker |
|
|
CN115160403A B16
[154]
|
Undisclosed |
Undisclosed |
CN115160403A+B7+payload |
CN115160403A+B11+Linker |
|
|
CN115160403A B17
[154]
|
Undisclosed |
Undisclosed |
CN115160403A+B7+payload |
CN115160403A+B17+Linker |
|
|
CN115160403A B18
[154]
|
Undisclosed |
Undisclosed |
CN115160403A+B7+payload |
CN115160403A+B18+Linker |
|
|
CN119072334A Formula 8
[155]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor H |
CN119072334A+Formula 8+Linker |
|
|
ThioBridge-Glu-[ (Val-Cit-PAB-MMáE)]2-Glu-[PEG (24u)]2
[155]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor H |
CN119072334A+ThioBridge⑪-Glu-[ (Val-Cit-PAB-MMáE)]2-Glu-[PEG (24u)]2+Linker |
|
|
DBCO-PEG3-vc-Exatecan
[156]
|
HuSS1 |
Undisclosed |
Exatecan |
DBCO-PEG3 linker |
|
|
DBCO-PEG3-GGFG-Exatecan
[156]
|
HuSS1 |
Undisclosed |
Exatecan |
EP4161582A4+DBCO-PEG3-GGFG-Exatecan+Linker |
|
|
DBCO-PEG12-GGFG-Exatecan
[156]
|
HuSS1 |
Undisclosed |
Exatecan |
EP4161582A4+DBCO-PEG12-GGFG-Exatecan+Linker |
|
|
BCN-PEG12-GGFG-Exatecan
[156]
|
HuSS1 |
Undisclosed |
Exatecan |
EP4161582A4+BCN-PEG12-GGFG-Exatecan +Linker |
|
|
AB1380049-SG3932 (DAR8)
[157]
|
AB1380049 |
Folate receptor alpha (FOLR1) |
(4-NH2)-Exatecan |
SG3932 Linker |
|
|
AB1380026-SG3932
[157]
|
AB1380026 |
Folate receptor alpha (FOLR1) |
(4-NH2)-Exatecan |
SG3932 Linker |
|
|
AB1380035-SG3932
[157]
|
AB1380035 |
Folate receptor alpha (FOLR1) |
(4-NH2)-Exatecan |
SG3932 Linker |
|
|
AB1380083-SG3932
[157]
|
AB1380083 |
Folate receptor alpha (FOLR1) |
(4-NH2)-Exatecan |
SG3932 Linker |
|
|
AB1380095-SG3932
[157]
|
AB1380095 |
Folate receptor alpha (FOLR1) |
(4-NH2)-Exatecan |
SG3932 Linker |
|
|
AB1380117-SG3932
[157]
|
AB1380117 |
Folate receptor alpha (FOLR1) |
(4-NH2)-Exatecan |
SG3932 Linker |
|
|
AB1380049-SG3932 (DAR4)
[157]
|
AB1380049 |
Folate receptor alpha (FOLR1) |
(4-NH2)-Exatecan |
SG3932 Linker |
|
|
CN119317630A ADC-C1
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
CN119317630A ADC-C2
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
CN119317630A ADC-C3
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C3 Linker |
|
|
CN119317630A ADC-C4
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C3 Linker |
|
|
CN119317630A ADC-C5
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C5 Linker |
|
|
CN119317630A ADC-C6
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C5 Linker |
|
|
CN119317630A ADC-C7
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C7 Linker |
|
|
CN119317630A ADC-C8
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C8 Linker |
|
|
CN119317630A ADC-C9
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C9 Linker |
|
|
CN119317630A ADC-C10
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C10 Linker |
|
|
CN119317630A ADC-C11
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C11 Linker |
|
|
CN119317630A ADC-C12
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C12 Linker |
|
|
CN119317630A ADC-C13
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C13 Linker |
|
|
CN119317630A ADC-C14
[158]
|
Ifinatamab |
CD276 antigen (CD276) |
DX-8951 derivative (DXd) |
CN119317630A ADC-C14 Linker |
|
|
30kmPEG (SCAHer2 (1)xSCAHer2 (2))-2 (Val-Cit-PAB-DEA-SN38)
[159]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
30kmPEG (SCAPDL1xSCACD47)-2 (Val-Cit-PAB-DEA-SN38)
[159]
|
Undisclosed |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
30kmPEG (SCAHer2 (1)xSCAHer2 (2))-3 (Val-Cit-PAB-DEA-SN38)
[159]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
30kmPEG (SCAPDL1xSCACD47)-3 (Val-Cit-PAB-DEA-SN38)
[159]
|
Undisclosed |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
30kmPEG (SCAPDL1xSCACD47)-4 (Val-Cit-PAB-DEA-SN38)
[159]
|
Undisclosed |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
EP4475894A1 20kmPEG (SCAPDL1xSCACD47)-2 (Val-Cit-PAB-DEA-SN38)
[159]
|
Undisclosed |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
SCAPDL1xSCACD47-20kPEG-2 (Val-Cit-PAB-DEA-SN38)
[159]
|
Undisclosed |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
30kmPEG (SCAPDL1xSCACD47)-2 (Val-Cit-PAB-DEA-Dxd)
[159]
|
Undisclosed |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
30kmPEG (SCAc-Met (1)xSCAc-Met (1))-2 (Val-Cit-PAB-DEA-SN38)
[159]
|
Undisclosed |
Hepatocyte growth factor receptor (MET) |
Active metabolite of irinotecan SN38 |
Undisclosed |
|
|
JP2024533562A ADC-4
[160]
|
Undisclosed |
Undisclosed |
EP4494658A1 antibody-drug conjugate 1 payload |
Mc-Val-Cit-PABC |
|
|
JP2024533562A ADC-12
[160]
|
Undisclosed |
Undisclosed |
EP4494658A1 antibody-drug conjugate 1 payload |
JP2024533562A ADC-16 linker |
|
|
US20240091372A1 3H9-KGDEVD-Exatecan
[161]
|
3H9 |
Prion-like protein doppel (PRND) |
Exatecan |
KGDEVD linker |
|
|
SG11202200215QA ADC3
[162]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
SG11202200215QA ADC3 linker |
|
|
SG11202200215QA ADC4
[162]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
SG11202200215QA ADC5 linker |
|
|
SG11202200215QA ADC5
[162]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
SG11202200215QA ADC5 linker |
|
|
WO2023232144A1ADC-2
[163]
|
anti-HER2 antibody mAb-1 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2023232144A1, ADC-2, Payload |
WO2023232144A1, ADC-2, linker |
|
|
WO2023232144A1ADC-3
[163]
|
anti-TROP2 antibody mAb-2 |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
WO2023232144A1, ADC-2, Payload |
WO2023232144A1, ADC-2, linker |
|
|
WO2023232144A1ADC-6
[163]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2023232144A1, ADC-2, Payload |
WO2023232144A1, ADC-2, linker |
|
|
WO2023232144A1ADC22
[164]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2025015586A1, ADC22, Payload |
Mc-Val-Cit-PABC |
|
|
WO2023232144A1ADC26
[164]
|
Avelumab |
Programmed cell death 1 ligand 1 (PD-L1) |
WO2025015586A1, ADC22, Payload |
Mc-Val-Cit-PABC |
|
|
WO2023232144A1ADC32
[164]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
WO2025015586A1, ADC22, Payload |
SMCC |
|
|
WO2023232144A1ADC33
[164]
|
Avelumab |
Programmed cell death 1 ligand 1 (PD-L1) |
WO2025015586A1, ADC22, Payload |
SMCC |
|
|
DS-1062
[165]
|
anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
WO2025019776A2ADC 22-8
[166]
|
A22 |
Interleukin-13 receptor subunit alpha-2 (IL13RA2) |
Belotecan |
WO2025019776A2, ADC 22-8, Linker |
|
|
WO2025019776A2ADC 33-8
[166]
|
A33 |
Interleukin-13 receptor subunit alpha-2 (IL13RA2) |
Belotecan |
WO2025019776A2, ADC 22-8, Linker |
|
|
WO2025019776A2ADC 52-8
[166]
|
A52 |
Interleukin-13 receptor subunit alpha-2 (IL13RA2) |
Belotecan |
WO2025019776A2, ADC 22-8, Linker |
|
|
WO2025019776A2ADC-00
[167]
|
P0 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2) |
Belotecan |
Undisclosed |
|
|
WO2025019776A2ADC-11
[167]
|
M1 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2) |
Belotecan |
Undisclosed |
|
|
WO2025019776A2ADC-13
[167]
|
M2 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2) |
Belotecan |
Undisclosed |
|
|
WO2025019776A2ADC-M3
[167]
|
M3 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2) |
Belotecan |
Undisclosed |
|
|
AU2023308528A1 ADC3
[168]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mal-amido-PEG8-acid |
|
|
AU2023308528A1 ADC4
[168]
|
huCDCP1 (F30-T667 Q525)-8xHis_T3 |
Undisclosed |
Exatecan |
Mal-amido-PEG8-acid |
|
|
AU2023308528A1 ADC5
[168]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
4- ((S)-2- ((S)-2-amino-3-methylbutanamido)propanamido)benzyl ((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)carbamate |
Mal-amido-PEG8-acid |
|
|
AU2023308528A1 ADC1
[168]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD aromatic-amide derivative |
6-Maleimidocaproic acid |
|
|
AU2023308528A1 ADC2
[168]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD-butanamide derivative |
6-Maleimidocaproic acid |
|
|
AU2023308528A1 ADC7
[168]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
N- (4- ((S)-2- ((S)-2-amino-3- methylbutanamido)propanamido)phenyl)-4- (4- (4- (4- (( (S)-2-methoxy-12-oxo-6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepin-3-yl)oxy)butanamido)-1-methyl-1H-pyrrole-2-carboxamido)phenyl)-1-methyl-1H-pyrrole-2-carboxamide |
(S)-75-oxo-76- (4- (3-tosyl-2- (tosylmethyl)propanoyl)benzamido) 2,5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71-tetracosaoxa-74 azanonaheptacontan-79-oic acid |
|
|
AU2023308528A1 ADC3 (DAR of 8)
[168]
|
huCDCP1 (F30-T667 Q525)-8xHis_T3 |
Undisclosed |
Exatecan |
Mal-amido-PEG8-acid |
|
|
AU2023308528A1 ADC2 (DAR of 4)
[168]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
PBD-butanamide derivative |
6-Maleimidocaproic acid |
|
|
Trastuzumab-Compound 30
[168]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mal-amido-PEG8-acid |
|
|
AU2023279443A1 Example 3
[169]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
U-030 |
AU2023279443A1, Example 4, Linker |
|
|
AU2023279443A1 Example A2
[169]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
U-030 |
Undisclosed |
|
|
AU2023279443A1 Example A10
[169]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Ac-Exatecan |
AU2023279443A1, Example A10, Linker |
|
|
AU2023279443A1 Example A11
[169]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
AU2023279443A1, Example A10, Linker |
|
|
AU2023279443A1 Example A13
[169]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
AU2023279443A1, Example A13, Linker |
|
|
AU2023279443A1 Example A20
[169]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor A |
AU2023279443A1, Example A12, Linker |
|
|
AU2023279443A1 Example A23
[169]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
RU20241285-23-payload |
AU2023279443A1, Example A10, Linker |
|
|
AU2023279443A1 Example A24
[169]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
RU20241285-23-payload |
AU2023279443A1, Example A24, Linker |
|
|
CN117337196A Compound53
[170]
|
SCAPDL1xSCACD47 |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
30kmPEG-Lys (Mal)-3 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound54
[170]
|
SCAPDL1xSCACD47 |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
30kmPEG-6 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound86
[170]
|
SCAHer2 (1)xSCAHer2 |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound87
[170]
|
SCAPDL1xSCACD47 |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound88
[170]
|
SCAHer2 (1)xSCAHer (2) |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
30kmPEG-Lys (PEG2 - Mal)-3 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound89
[170]
|
SCAPDL1xSCACD47 |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
30kmPEG-Lys (PEG2 - Mal)-3 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound90
[170]
|
SCAPDL1xSCACD47 |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
30kmPEG-Lys (PEG2 - Mal)-4 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound91
[170]
|
SCAPDL1xSCACD47 |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
20kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound92
[170]
|
SCAPDL1xSCACD47 |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Active metabolite of irinotecan SN38 |
(PEG2 -Mal) - 20kPEG-2 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound93
[170]
|
SCAPDL1xSCACD47 |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
DX-8951 derivative (DXd) |
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA) |
|
|
CN117337196A Compound94
[170]
|
SCAc-Met (1)xSCAc-Met (2) |
Hepatocyte growth factor receptor (MET) |
Active metabolite of irinotecan SN38 |
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA) |
|
|
CN113943310A ADC-1
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D9 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-2
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D10 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-3
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D3 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-4
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D4 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-5
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D5 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-6
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D6 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-7
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D11 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-8
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D12 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-9
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D14 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-10
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
D-D1 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-14
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
compound 4 |
CN113943310A, ADC-12, Linker |
|
|
CN113943310A ADC-15
[171]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
compound 5 |
CN113943310A, ADC-12, Linker |
|
|
CN113943310A ADC-19
[171]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
D-D3 payload |
CN113943310A, ADC-1, Linker |
|
|
CN113943310A ADC-20
[171]
|
Cetuximab |
Epidermal growth factor receptor (EGFR) |
D-D7 payload |
CN113943310A, ADC-1, Linker |
|
|
WO2024239281A1 C031
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-Gly amide |
Mal-PEG-Ala-Ala-Ala linker |
|
|
WO2024239281A1 C039
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-Gly amide |
Mal-PEG-Val-Ala linker |
|
|
WO2024239281A1 C054
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
Mal-PEG-Val-Ala linker |
|
|
WO2024239281A1 C060
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-carbamate (aminoethyl) |
Mal-PEG-Val-Ala linker |
|
|
WO2024239281A1 C078
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-L-Ala amide |
Maleimide-PEG-L-Valine linker |
|
|
WO2024239281A1 C084
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-Gly amide |
Bis-maleimide-PEG linker |
|
|
WO2024239281A1 C084C
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-Gly amide |
WO2024239281A1, C084C, Linker |
|
|
WO2024239281A1 C112
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-Gly amide |
WO2024239281A1, C112, Linker |
|
|
WO2024239281A1 C117
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C117, Linker |
|
|
WO2024239281A1 C144
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-Gly amide |
WO2024239281A1, C144, Linker |
|
|
WO2024239281A1 C158
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-Gly amide |
WO2024239281A1, C158, Linker |
|
|
WO2024239281A1 C193
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
(R)-5- (3- ((S)-2- ((S)-2-amino-3-methylbutanamido)propanamido)-4- hydroxyphenyl)-4- (2- ((6S,9R,11R)-6- ((S)-sec-butyl)-9-isopropyl-2,3,3,8-tetramethyl-4,7,13-trioxo-12-oxa-2,5,8-triazatetradecan-11-yl)thiazole-4-carboxamido)pentanoic acid |
WO2024239281A1, C193, Linker |
|
|
WO2024239281A1 C200
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
(R)-5- (3- ((S)-2- ((S)-2-amino-3-methylbutanamido)propanamido)-4- hydroxyphenyl)-4- (2- ((6S,9R,11R)-6- ((S)-sec-butyl)-9-isopropyl-2,3,3,8-tetramethyl-4,7,13-trioxo-12-oxa-2,5,8-triazatetradecan-11-yl)thiazole-4-carboxamido)pentanoic acid |
WO2024239281A1, C200, Linker |
|
|
WO2024239281A1 C207
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C207, Linker |
|
|
WO2024239281A1 C207C
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C207C, Linker |
|
|
WO2024239281A1 C213
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-phenoxy-Ala |
Maleimide-PEG-L-Valine linker |
|
|
WO2024239281A1 C218
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
4- ((S)-2-aminopropanamido)benzyl (2- ((S)-4,11-diethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)oxy)ethyl)carbonate |
WO2024239281A1, C218, Linker |
|
|
WO2024239281A1 C225
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
2- (( (S)-4,11-diethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)oxy)ethyl (4- ((S)-2-aminopropanamido)benzyl)carbamate |
Maleimide-PEG-L-Valine linker |
|
|
WO2024239281A1 C230
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-phenoxy-PEG2-Ala |
Maleimide-PEG-L-Valine linker |
|
|
WO2024239281A1 C237
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-PEG2-Ala |
Maleimide-PEG-L-Valine linker |
|
|
WO2024239281A1 C257
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C257, Linker |
|
|
WO2024239281A1 C263
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C263, Linker |
|
|
WO2024239281A1 C266
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C266, Linker |
|
|
WO2024239281A1 C266C
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C266C, Linker |
|
|
WO2024239281A1 C269
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C269, Linker |
|
|
WO2024239281A1 C269C
[172]
|
Vandortuzumab |
Metalloreductase STEAP1 (STEAP1) |
Exatecan-aminoethoxy |
WO2024239281A1, C269C, Linker |
|
|
WO2024181570A1 ADC5
[173]
|
Antibody 1 |
Syndecan-1 (SDC1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
WO2024181570A1 ADC6
[173]
|
Antibody 1 |
Syndecan-1 (SDC1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
WO2024105206A1 2i-5657
[141]
|
TPP-5657 |
Undisclosed |
Camptothecin |
2i-5657 Linker |
|
|
WO2024105206A1 2k-2658
[141]
|
TPP-2658 |
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) |
Camptothecin |
2i-5657 Linker |
|
|
WO2024105206A1 3i-5657
[141]
|
TPP-5657 |
Undisclosed |
Ac-Exatecan |
32p-Avelu Linker |
|
|
WO2024105206A1 3k-2658
[141]
|
TPP-2658 |
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) |
Ac-Exatecan |
32p-Avelu Linker |
|
|
WO2024105206A1 5k-2658
[141]
|
TPP-2658 |
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) |
6i-5657 Payload |
3i-5657 Linker |
|
|
WO2024105206A1 6i-5657
[141]
|
TPP-5657 |
Undisclosed |
6i-5657 Payload |
3i-5657 Linker |
|
|
WO2024105206A1 6k-2658
[141]
|
TPP-2658 |
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) |
6i-5657 Payload |
3i-5657 Linker |
|
|
WO2024105206A1 8i-5657
[141]
|
TPP-5657 |
Undisclosed |
Mdo-cpt |
Undisclosed |
|
|
WO2024105206A1 10i-5657
[141]
|
TPP-5657 |
Undisclosed |
Ac-Exatecan |
CHH0187, 10i-5657, Linker |
|
|
WO2020252015A1 ADCLP-2
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-SO3-PEG4-Val-Cit-PABC |
|
|
WO2020252015A1 ADCLP-3
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-B-Glucuronide-PEG12 |
|
|
WO2020252015A1 ADCLP-5
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-AAN |
|
|
WO2020252015A1 ADCLP-6
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nnAA-PEG13-AAA |
|
|
WO2020252015A1 ADCLP-7
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-nAA-PEG13-VKG |
|
|
WO2015115091A1 ADCLP-10
[175]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
DX-8951 derivative (DXd) |
DBCO-PEG4-GGFG-aminol |
|
|
WO2020252015A1 ADCLP-14
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6,4nnAA-PEG-VKG |
|
|
WO2020252015A1 ADCLP-15
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-4,6nnAA-PEG-VKG |
|
|
WO2020252015A1 ADCLP-16
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-4,4nnAA-PEG-VKG |
|
|
WO2016102679A1 ADCLP-17
[176]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-BridgednnAA-PEG-VKG |
|
|
WO2020252015A1 ADCLP-18
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6.6nnAA-B-Glucuronide-PEG1 |
|
|
WO2020252015A1 ADCLP-19
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-6.4nnAA-B-Glucuronide-PEG12 |
|
|
WO2020252015A1 ADCLP-20
[174]
|
mAb42 |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Exatecan |
DBCO-4.4 nAA-B-Glucuronide-PEG12 |
|
|
SWY2110-JSSW-001 ADC
[177]
|
SWY2110 |
Epidermal growth factor receptor (EGFR) |
Exatecan |
C12-1 linker |
|
|
SWY2111-JSSW-001 ADC
[177]
|
SWY2111 |
Epidermal growth factor receptor (EGFR) |
Exatecan |
C12-1 linker |
|
|
SWY2112-JSSW-001 ADC
[177]
|
SWY2112 |
Epidermal growth factor receptor (EGFR) |
Exatecan |
C12-1 linker |
|
|
SWY2113-JSSW-001 ADC
[177]
|
SWY2113 |
Epidermal growth factor receptor (EGFR) |
Exatecan |
C12-1 linker |
|
|
SWY2110-GGFG-DXD ADC
[177]
|
SWY2110 |
Epidermal growth factor receptor (EGFR) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
VH4Vk3-CL2A-SN38 ADC
[178]
|
VH4Vk3 |
Ephrin type-A receptor 5 (EPHA5) |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
VH4Vk3-ThioBridge- (VCP)2-SN38 ADC
[178]
|
VH4Vk3 |
Ephrin type-A receptor 5 (EPHA5) |
Active metabolite of irinotecan SN38 |
ThioBridge- (VCP)2 linker |
|
|
DDR1 ADC
[179]
|
Undisclosed |
Epithelial discoidin domain-containing receptor 1 (DDR1) |
DX-8951 derivative (DXd) |
Mc-Gly-Gly-Phe-Gly |
|
|
mAb-P5 (PEG24)- VC-PAB-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG24)- VC-PAB linker |
|
|
mAb-P5 (PEG2)- VC-PAB-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG2)- VC-PAB linker |
|
|
mAb-P5 (PEG12)- VC-PAB-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG12)- VC-PAB linker |
|
|
mAb-P5 (PEG2)-VA-PAB-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG2)-VA-PAB linker |
|
|
mAb-P5 (PEG12)-VA-PAB-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG12)-VA-PAB linker |
|
|
mAb-P5 (PEG24)-VA-PAB-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG24)-VA-PAB linker |
|
|
mAb-P5 (PEG2)-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG2) linker |
|
|
mAb-P5 (PEG12)-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG12) linker |
|
|
mAb-P5 (PEG24)-Exatecan
[180]
|
AV-25 |
N-myc downstream-regulated gene 2B (NDRG2B) |
Exatecan |
P5 (PEG24) linker |
|
|
MAb-CL2A-SN-38
[181]
|
hL243 |
human leukocyte antigen-DR |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
hMN-14-CL2A-SN-38
[181]
|
hMN-14 |
human leukocyte antigen-DR |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
hRS7-CL2A-SN-38
[181]
|
hRS7 |
human leukocyte antigen-DR |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
hA20-CL2A-SN-38
[181]
|
hA20 |
human leukocyte antigen-DR |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
hLL2-CL2A-SN-38
[181]
|
hLL2 |
human leukocyte antigen-DR |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
hPAM4-CL2A-SN-38
[181]
|
hPAM4 |
human leukocyte antigen-DR |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
WO2021260582A1 ADC-1
[182]
|
Undisclosed |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Mc-Gly-Gly-Phe-Gly |
|
|
CN113813399A ADC:LN401-34-3
[183]
|
Undisclosed |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Active metabolite of irinotecan SN38 |
CN113813399A-ADC:LN401-34-3-linker |
|
|
CN110974975B C-01
[184]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Coumpound7 |
|
|
CN110974975B C-06
[184]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Exatecan |
Coumpound15 |
|
|
CN110974975B C-07
[184]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Active metabolite of irinotecan SN38 |
Coumpound17 |
|
|
WO2022099762A1 ADCa
[185]
|
M30-H1-L4P |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Camptothecin |
WO2022099762A1 10 |
|
|
WO2022099762A1 ADCb
[185]
|
M30-H1-L4P |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Camptothecin |
Mc-Gly-Gly-Phe-Gly |
|
|
BCN-linker-Dxd1
[186]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
BCN-linker |
|
|
BCN-linker-Dxd2
[186]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
BCN-linker |
|
|
BCN-linker-Dxd3
[186]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
BCN-linker |
|
|
BCN-linker-Dxd4
[186]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
BCN-linker |
|
|
CN115429890B ADC-1
[187]
|
Undisclosed |
Epidermal growth factor receptor (EGFR) |
Active metabolite of irinotecan SN38 |
DBCO-PEG8-glu |
|
|
CN115429890B ADC-2
[187]
|
Undisclosed |
Epidermal growth factor receptor (EGFR) |
Active metabolite of irinotecan SN38 |
DBCO-Val-Cit-PABC |
|
|
TWI870307BAntibody-drug conjugate (2)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
TWI870307BAntibody-drug conjugate (3)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
TWI870307BAntibody-drug conjugate (4)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
TWI870307BAntibody-drug conjugate (4)Linker |
|
|
TWI870307BAntibody-drug conjugate (5)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
TWI870307BAntibody-drug conjugate (4)Linker |
|
|
TWI870307BAntibody-drug conjugate (6)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
TWI870307BAntibody-drug conjugate (6)Linker |
|
|
TWI870307BAntibody-drug conjugate (7)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
TWI870307BAntibody-drug conjugate (6)Linker |
|
|
TWI870307BAntibody-drug conjugate (8)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
TWI870307BAntibody-drug conjugate (6)Linker |
|
|
TWI870307BAntibody-drug conjugate (9)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
TWI870307BAntibody-drug conjugate (9)Linker |
|
|
TWI870307BAntibody-drug conjugate (10)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
TWI870307BAntibody-drug conjugate (9)Linker |
|
|
TWI870307BAntibody-drug conjugate (24)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC25 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
TWI870307BAntibody-drug conjugate (25)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC25 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
TWI870307BAntibody-drug conjugate (36)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
TWI870307BAntibody-drug conjugate (36)Linker |
|
|
TWI870307BAntibody-drug conjugate (37)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
TWI870307BAntibody-drug conjugate (36)Linker |
|
|
TWI870307BAntibody-drug conjugate (41)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor B |
Mc-Gly-Gly-Phe-Gly |
|
|
TWI870307BAntibody-drug conjugate (42)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor B |
Mc-Gly-Gly-Phe-Gly |
|
|
TWI870307BAntibody-drug conjugate (43)
[188]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
TWI870307BAntibody-drug conjugate (6)Linker |
|
|
LT4212552T ADC-3
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC5
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
LT4212552T-ADC-5-LINKER |
|
|
LT4212552T ADC7
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
LT4212552T-ADC-7-LINKER |
|
|
LT4212552T ADC8
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
LT4212552T-ADC-8-LINKER |
|
|
LT4212552T ADC9
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
LT4212552T-ADC-9-LINKER |
|
|
LT4212552T ADC10
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC10 payload |
LT4212552T-ADC-10-LINKER |
|
|
LT4212552T ADC13
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC13 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC15
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
Undisclosed |
|
|
LT4212552T ADC16
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
Undisclosed |
|
|
LT4212552T ADC17
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
LT4212552T-ADC-17-LINKER |
|
|
LT4212552T ADC18
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
LT4212552T-ADC-17-LINKER |
|
|
LT4212552T ADC19
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
LT4212552T-ADC-19-LINKER |
|
|
LT4212552T ADC20
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
LT4212552T-ADC-19-LINKER |
|
|
LT4212552T ADC21
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
LT4212552T-ADC-21-LINKER |
|
|
LT4212552T ADC22
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
LT4212552T-ADC-21-LINKER |
|
|
LT4212552T ADC24
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC25 payload |
LT4212552T-ADC-24-LINKER |
|
|
LT4212552T ADC25
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC25 payload |
LT4212552T-ADC-24-LINKER |
|
|
LT4212552T ADC26
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC27
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC28
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC29
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC30
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC31
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC36
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
LT4212552T-ADC-36-LINKER |
|
|
LT4212552T ADC37
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC37 payload |
LT4212552T-ADC-36-LINKER |
|
|
LT4212552T ADC41
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor B |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC42
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor B |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC43
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
LT4212552T-ADC-6-LINKER |
|
|
LT4212552T ADC44
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
HK40112172A+Antibody-drug conjugate (44)+Linker |
|
|
LT4212552T ADC46
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC47
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
LT4212552T ADC49
[189]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
LT4212552T ADC49 payload |
Mc-Gly-Gly-Phe-Gly |
|
|
TW202506738A C-009
[190]
|
Undisclosed |
Undisclosed |
TW202506738A-C-009-PAYLOAD |
TW202506738A-C-009-LINKER |
|
|
TW202506738A C-020
[190]
|
Undisclosed |
Undisclosed |
TW202506738A-C-009-PAYLOAD |
TW202506738A-C-020-LINKER |
|
|
TW202506738A C-096
[190]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor E |
TW202506738A-C-096-LINKER |
|
|
TW202506738A C-111
[190]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor E |
TW202506738A-C-111-LINKER |
|
|
TW202506738A C-133
[190]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor E |
TW202506738A-C-133-LINKER |
|
|
TW202506738A C-155
[190]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor E |
TW202506738A-C-155-LINKER |
|
|
TW202506738A C-168
[190]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor E |
TW202506738A-C-168-LINKER |
|
|
TW202506738A C-172
[190]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor E |
TW202506738A-C-172-LINKER |
|
|
TW202506738A C-182
[190]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor G |
TW202506738A-C-182-LINKER |
|
|
TW202506738A C-186
[190]
|
Undisclosed |
Undisclosed |
Topo1 inhibitor G |
TW202506738A-C-186-LINKER |
|
|
TW202506738A C-208
[190]
|
Undisclosed |
Undisclosed |
Exatecan |
TW202506738A-C-208-LINKER |
|
|
EP4487874A1-12
[191]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
EP4487874A1-12linker |
|
|
EP4487874A1-14
[191]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
EP4487874A1-14linker |
|
|
EP4487874A1-18
[191]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor A |
EP4487874A1-18linker |
|
|
EP4487874A1-19
[191]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
RU20241285-23-payload |
EP4487874A1-19linker |
|
|
EP4487874A1-21
[191]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
RU20241285-23-payload |
RU20241285-19-linker |
|
|
EP4487874A1-22
[191]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Topo1 inhibitor A |
EP4487874A1-22linker |
|
|
EP4487874A1-25
[191]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
RU20241285-23-payload |
EP4487874A1-23linker |
|
|
EP4487874A1-26
[191]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
RU20241285-23-payload |
EP4487874A1-24linker |
|
|
Murinized SG
[192]
|
mRS7 |
Undisclosed |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
Surrogate SG
[192]
|
Rab64 |
Undisclosed |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
Control surrogate and mouse SG
[192]
|
mMAB1129 |
Undisclosed |
Active metabolite of irinotecan SN38 |
CL2A |
|
|
38354417 T-DL1
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
FD1 |
MT-GGFG-AM |
|
|
38354417 T-DL3
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
FD2 |
MT-GGFG-AM |
|
|
38354417 T-DL4
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
FD3 |
MT-GGFG-AM |
|
|
38354417 T-DL9
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
10NH2-11F-Camptothecin |
MT-GGFG-AM |
|
|
38354417 T-DL5
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
FD5 |
MT-GGFG-AM |
|
|
38354417 T-DL6
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
FD5 |
Mc-Gly-Gly-Phe-Gly |
|
|
38354417 T-DL11
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
FD5 |
MT-GGFG-AM |
|
|
38354417 T-DL13
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
FD6 |
MT-GGFG-AM |
|
|
38354417 T-DL14
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
FD7 |
MT-GGFG-AM |
|
|
38354417 T-DL7
[193]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DX-8951 derivative (DXd) |
MT-GGFG-AM |
|
|
MGC028
|
Anti-ADAM9 antibody |
Disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) |
Exatecan |
Bicyclononyne carbamoyl sulfamide Val-Ala-PABC |
|
|
AK138D1
|
Patritumab |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
DXd |
Mc-Ala-Ala-Ala |
|
|
SHR-1681
|
Anti-HER3/c-Met bsAb |
Receptor tyrosine-protein kinase erbB-3 (HER3); Hepatocyte growth factor receptor (MET) |
TOP1 inhibitor |
Undisclosed |
|
|
SKB445
|
Anti-CDH3 antibody |
Cadherin-3 (CDH3) |
KL610348 |
A cleavable linker |
|
|
ADCE-D01
|
Anti-MRC2 antibody |
C-type mannose receptor 2 (MRC2) |
P1021 |
A cleavable linker |
|
|
ZPC-21
|
Anti-ROR1 mAb |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
HC74 |
A cleavable linker |
|
|
ESG406
|
Anti-TROP2 mAb |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
Exatecan |
A cleavable linker |
|
|
YL217
|
Anti-CDH17 antibody |
Cadherin-17 (CDH17) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
MHB046C
|
MHB046A |
CDCP1 |
MH30010008 |
A cleavable linker |
|
|
HS-20108
|
Anti-SEZ6 antibody |
Seizure protein 6 homolog (SEZ6) |
TOP1 inhibitor |
Undisclosed |
|
|
SIM 0686
|
Anti-FGFR2b IgG1 antibody |
Fibroblast growth factor receptor 2 (FGFR2) |
CPT116 |
A cleavable linker |
|
|
SIBP-A19
|
SIBP-A12 |
Folate receptor alpha (FOLR1) |
DXd |
Mc-VASGFG |
|
|
AK146D1
|
Anti-nectin-4/TROP2 bsAb |
Nectin-4 (NECTIN4); Tumor-associated calcium signal transducer 2 (TACSTD2) |
DXd |
Mc-Ala-Ala-Ala |
|
|
BL-M09D1
|
Anti-CEA mAb |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
Ed-04 |
Gly-Mal-Gly-Gly-Phe-Gly |
|
|
SIBP-A18
|
Anti-CLDN18.2 antibody |
Claudin-18.2 (CLDN18.2) |
DXd |
Mc-VASGFG |
|
|
SKB518
|
Anti-PTK7 antibody |
Inactive tyrosine-protein kinase 7 (PTK7) |
KL610348 |
Kthiol (pyrimidine-thiol) GGFG linker |
|
|
MRG007
|
Anti-CDH17 mAb |
Cadherin-17 (CDH17) |
Exatecan |
Undisclosed |
|
|
XNW28012
|
Anti-tissue factor antibody |
Tissue factor (F3) |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
LY4175408
|
Anti-PTK7 mAb |
Inactive tyrosine-protein kinase 7 (PTK7) |
Exatecan |
A proprietary polysarcosine hydrophobicity linker |
|
|
HDM2020
|
Anti-FGFR2 antibody |
Fibroblast growth factor receptor 2 (FGFR2) |
TOP1 inhibitor |
A cleavable linker |
|
|
HDM2012
|
Anti-Muc17 antibody |
Mucin-17 |
TOP1 inhibitor |
A cleavable linker |
|
|
RC278
|
Anti-CDCP1 antibody |
CUB domain-containing protein 1 (CDCP1) |
TOP1 inhibitor |
A cleavable linker |
|
|
ALX2004
|
Anti-EGFR antibody |
Epidermal growth factor receptor (EGFR) |
TOP1 inhibitor |
Undisclosed |
|
|
ICP-B794
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
TOP1 inhibitor |
A cleavable linker |
|
|
BNT3212
|
Anti-EGFR/HER3 bsAb |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3) |
TOP1 inhibitor |
A cleavable linker |
|
|
DB-1317
|
Anti-ADAM9 antibody |
Disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) |
TOP1 inhibitor |
Undisclosed |
|
|
BG-C0902
|
Anti-EGFR/c-Met bsAb |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
TOP1 inhibitor |
A cleavable linker |
|
|
BNT329
|
Anti-CA19-9 antibody |
CA19-9 |
YL0010014 |
VK*G-NHCH2-O linker |
|
|
VBC103
|
Anti-Nectin-4/TROP2 bispecific VHH-Fc |
Nectin-4 (NECTIN4); Tumor-associated calcium signal transducer 2 (TACSTD2) |
TOP1 inhibitor |
Undisclosed |
|
|
FS001
|
Undisclosed |
Undisclosed |
TOP1 inhibitor |
A cleavable linker |
|
|
sofetabart mipitecan
|
Sofetabart |
Folate receptor alpha (FOLR1) |
Exatecan |
Mal-Polysarcosine10-Val-Ala-PABC |
|
|
7MW4911
|
Mab0727 |
Cadherin-17 (CDH17) |
Mtoxin |
A cleavable disulfide linker |
|
|
MRG006
|
Anti-GPC3 mAb |
Glypican-3 (GPC3) |
Novel TOP1 inhibitor |
MCC-AAQ |
|
|
SKB571
|
Anti-EGFR/c-Met bsAb |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
KL610348 |
Kthiol (pyrimidine-thiol) AAA linker |
|
|
izalontamab brengitecan
|
Izalontamab |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3) |
Ed-04 |
Gly-Mal-Gly-Gly-Phe-Gly |
|
|
FH-006
|
MG2303 |
CD276 antigen; Epidermal growth factor receptor (EGFR) |
SHR9265 |
Mc-Gly-Gly-Phe-Gly |
|
|
SYS6043
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
JS-1 |
Mc-Gly-Gly-Phe-Gly |
|
|
GenSci139
|
Anti-EGFR/HER2 bsAb |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-2 (HER2) |
GSC5181 |
A cleavable linker |
|
|
DS3790a
|
Anti-CD37 mAb |
Leukocyte antigen CD37 (CD37) |
DXd |
Mc-Gly-Gly-Phe-Gly |
|
|
GenSci143
|
Anti-B7H3/PSMA bsAb |
CD276 antigen; Glutamate carboxypeptidase 2 (FOLH1) |
GSC5181 |
A cleavable linker |
|
|
GenSci140
|
Anti-FRα antibody |
Folate receptor alpha (FOLR1) |
GSC5181 |
A cleavable linker |
|
|
SKB500
|
Anti-B7H3 antibody |
CD276 antigen (CD276) |
KL610348 |
A cleavable linker |
|
|
HS-20110
|
Anti-CDH17 antibody |
Cadherin-17 (CDH17) |
HS-9265 |
Undisclosed |
|
|
TQB6411
|
Anti-EGFR/c-Met bsAb |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
2-DDDX-d |
A cleavable linker |
|
|
DEC006
|
Undisclosed |
Inactive tyrosine-protein kinase 7 (PTK7) |
CPT113 |
Highly stable yet cleavable linker |
|
|
SKB105
|
Anti-ITGB6 full human IgG1 |
Integrin beta-6 (ITGB6) |
TOP1 inhibitor |
Kthiol (pyrimidine-thiol) oligopeptide linker |
|
|
SHR-4394
|
Anti-PSMA mAb |
Glutamate carboxypeptidase 2 (FOLH1) |
SHR9265 |
A cleavable linker |
|
|
BCG034
|
Anti-B7H3/PTK7 bsAb |
CD276 antigen; Inactive tyrosine-protein kinase 7 (PTK7) |
BCPT02 |
Hydrophilic, protease-cleavable linker |
|
|
LCB02A
|
HClaudin18.2 |
Claudin-18.2 (CLDN18.2) |
PR301839 |
Undisclosed |
|
|
BMS-986490
|
Anti-CEA antibody |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) |
TOP1 inhibitor |
Undisclosed |
|
|
HS-20105
|
Anti-TROP2 antibody |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
TOP1 inhibitor |
A cleavable linker |
|
|
IBI133
|
Anti-HER3 mAb |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
Exatecan |
A cleavable linker |
|
|
MGC026
|
Vobramitamab |
CD276 antigen (CD276) |
Exatecan |
Bicyclononyne carbamoyl sulfamide Val-Ala-PABC |
|
|
SGN-35C
|
Brentuximab |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) |
AMDCPT |
A cleavable linker |
|
|
SHR-7631
|
Anti-LIV-1 mAb |
Zinc transporter ZIP6 (SLC39A6) |
SHR9265 |
Undisclosed |
|
|
FZ-AD005
|
Anti-DLL3 antibody |
Delta-like protein 3 (DLL3) |
DXd |
Mc-Val-Ala-PABC double self-immolative linker |
|
|
SIBP-A17
|
Anti-HER2 antibody |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
DXd |
Mc-VASGFG |
|
|
SYS6023
|
Anti-HER3 mAb |
Receptor tyrosine-protein kinase erbB-3 (HER3) |
Self-developed TOP1 inhibitor |
Undisclosed |
|
|
IBI3009
|
Anti-DLL3 mAb |
Delta-like protein 3 (DLL3) |
NT1 |
Undisclosed |
|
|
HS-20124
|
Anti-CDH6 antibody |
Cadherin-6 (CDH6) |
SHR9265 |
Undisclosed |
|
|
M3554
|
Anti-GD2 antibody |
Ganglioside GD2 (GD2) |
Exatecan |
Mal-glucuronide-PABC |
|
|
ALK201
|
Anti-FGFR2 mAb |
Fibroblast growth factor receptor 2 (FGFR2) |
Exatecan |
A cleavable linker |
|
|
ALK202
|
Anti-EGFR/c-Met bsAb |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
Exatecan |
Undisclosed |
|
|
SIM0505
|
Anti-CDH6 antibody |
Cadherin-6 (CDH6) |
CPT116 |
A cleavable linker |
|
|
IBI3014
|
Anti-PDL1/TROP2 bsAb |
Programmed cell death 1 ligand 1 (PD-L1); Tumor-associated calcium signal transducer 2 (TACSTD2) |
NT1 |
A cleavable linker |
|
|
SHR-3792
|
Anti-EGFR/Muc1 bsAb |
Epidermal growth factor receptor (EGFR); Mucin-1 (MUC1) |
TOP1 inhibitor |
A cleavable linker |
|
|
AZD4360
|
Anti-CLDN18.2 antibody |
Claudin-18.2 (CLDN18.2) |
TOP1 inhibitor |
Undisclosed |
|
|
SYS6045
|
Anti-HER2 antibody |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
TOP1 inhibitor |
Undisclosed |
|
|
QLS5133
|
Anti-CDH6 antibody |
Cadherin-6 (CDH6) |
QLS6916 |
A cleavable linker |
|
|
AZD4512
|
Anti-CD22 antibody |
B-cell receptor CD22 (CD22) |
TOP1 inhibitor |
A cleavable linker |
|
|
ALE.P03
|
H1L1 |
Claudin-1 (CLDN1) |
Exatecan |
Mc-Gly-Gly-Phe-Gly |
|
|
SIM0609
|
Anti-CDH17 antibody |
Cadherin-17 (CDH17) |
CPT116 |
A cleavable linker |
|
|
YLSH003
|
Anti-tissue factor antibody |
Tissue factor (F3) |
TOP1 inhibitor |
A cleavable linker |
|
|
BC2027
|
Anti-GPC3 antibody |
Glypican-3 (GPC3) |
TOP1 inhibitor |
A cleavable linker |
|
|
KIVU-107
|
Anti-PTK7 IgG1 mAb |
Inactive tyrosine-protein kinase 7 (PTK7) |
Exatecan |
Undisclosed |
|
|
ADCX-020
|
Undisclosed |
Undisclosed |
TOP1 inhibitor |
A cleavable linker |
|
|
JS212
|
Anti-EGFR/HER3 bsAb |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3) |
Exatecan |
A cleavable linker |
|
|
SIM0610
|
Anti-EGFR/c-Met bsAb |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
TOP1 inhibitor |
A cleavable hydrophilic linker |
|
|
M7437
|
Anti-Ly6E antibody |
Lymphocyte antigen 6E (LY6E) |
Exatecan |
Undisclosed |
|
|
QLS5316
|
Anti-EGFR/c-Met bsAb |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR) |
QLS6916 |
A cleavable linker |
|
|
JSKN027
|
Anti-PDL1/TVEGFR2 bsAb |
Programmed cell death 1 ligand 1 (PD-L1); Vascular endothelial growth factor A (VEGFA) |
TOP1 inhibitor |
A cleavable linker |
|
|
BG-C0979
|
Anti-ADAM9 antibody |
Disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) |
TOP1 inhibitor |
Undisclosed |
References